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ABSTRACT
A method for determining the nature of a sample is provided,
wherein the presence or absence of at least one marker small
non-coding RNA in the sample is detected. Suitable marker
small non-coding RNAs for different samples such as blood,
saliva, semen and vaginal secretions are provided. Also provided are suitable kits and methods for identifying marker
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Table 1: Small non-coding RNAa sullllble u blood mark&!'$

miRNA
tet7a
let7b
iet7c
let7d

~"
1817f

~~~
m•R7

Huma~ miRNAe
hsa-laHa-UGAGGUAGUAGGUUGUAUAGUU - SEQ ID NO ,
tisa·let-7t>-UGAGGUAGUAGGUUGUGUGGUU - SEQ 10 NO 2

Ma-lat-7c-UGAGGUAGUAGGUUGUAUGGUU - SEQ ID NO 3
Ma-tet-711-AGAGGUAGUAGGUUGCAUAGUU. SEQ ID NO 4

hsa-let-7&-UGAGGUAGGAGGUUGUAUAGUU ·SEO 10 NO S
hsa-~t-7!-UGAGGUAGUAGAUUGUAUAGUU ·SEQ ID NO 6
hsa-ieH~UGAGGUAGUAGUUUGUACAGUU ·SEQ ID NO 7
hS8·1et-7~UGAGGUAGUAGUUUGUGCUGUU ·SEQ ID NO· 8
hsa-mlR-7-UGGAAGACUAGUGAUUUUGUUGU. SEQ ID NO: 9

miR1S
mlR17
mlR18alb

hsa-mlR-158-UAGCAGCACAUAAUGGUUUGUG - SEQ ID NO 10
hsa·mlR-15b·UAGCAGCACAUCAUGGUUUACA ·SEQ 10 NO. 11
nsa-m•R-16-UAGCAGCACGUAAAUAUUGGCG. SEQ 10 NO 12
Ma-mlR-17-CAAAGUGCUUACAGUGCAGGUAG - SEQ ID NO 13
hsa·'™R-11!a·UAAGGUGCAUCUAGUGCAGAUAG - SEQ ID NO 14

mlR18a"
mlR19a
mrR20a
mlR25
mlR26b
m<R30b
m1R30ale·

h""·m1R-181l.UAAGGUGCAUCUAGUGCAGUUAG ·SEQ ID NO· 15
hsa-m1R-11!a"-ACUGCCCUAAGUGCUCCUUCUGG ·SEQ ID NO 16
h ...m1R-19a.UGUGCAAAUCUAUGCAAAACUGA- SEQ ID NO 17
hsa-mlR-20..-UAAAGUGCUUAUAGUGCAGGUAG ·SEQ ID NO. 18
h..·ITllR-25-CAUUGCACUUGUCUCGGUCUGA - sea ID NO 19
h:;a-m!A-25b--UUCAAGUAAUUCAGGAUAGGU ·SEQ ID NO· 20
hsa-miR-JOb-UGUAMCAUCCUACACUCAGCU - SEO ID NO 21
hsa-mlR-30a-UGUAAACAUCCUCGACUGGAAG - SEO ID NO· 22

mlR1Ga
mlR15b

'"
miR93
mrR96
m1R103

mlR106b
m1R107
mlR126
m1R125"
miR12B
mlfl130a
miR149b

hsa-mll'l-3Cle- UGUAAACAUCCUUGACUGGAAG- pr~IB!Ted ·SEO ID NO· 23
hsa-mll'l-93-CAMGUGCUGUUCGUGCAGGUAG ·SEQ ID NO· 24
hsa-m•R-95-UUUOOCACUAGCACAUUUUUGCU ·SEQ ID NO. 25
hsa-moR-103-AGCAGCAUUGUACAGGGCUAUGA- sea ID NO 26
//hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA. sea ID NO 29
h$1i-mlR-106o-AAAAGUGCUUACAGUGCAGGUAG - sea ID NO 27
// hsa-m•Fl-1 7-CAAAGUGCUUACAGUGCAGGUAG • SEQ 10 NO 13
hsa-m1R-106~UAAAGUGCUGACAGUGCAGAU - SEQ ID NO 28
hsa-mlR-107-AGCAGCAUUGUACAGGGCUAUCA- SEQ 10 NO 29
h:!<l·mlR· 126-UCGUACCGUGAGUAAUAAUGCG • SEO ID NO 30
hsa-mlR-12e·-CAUUAUUACUUUUGGUACOCG-SEOIDNO 31
has-miR-128-UCACAGUGAACCGGUCUCUUU ·SEQ ID NO. 32
hsa-mlR-130a-CAGUGCAAUGUUAAAAOGGCAU - SEQ 10 NO: 33
hs'1-m1R-14aa-UCAGUGCACUACAGAACUUUGU ·SEO ID NO 34
hs•-mlR-14&-UCAGUGCAUCACAGAACUUUGU ·SEQ ID NO: 35
hsi0-m1R·14Sa'·AAAGUUCUGAGACACUCCGACU ·SEQ ID NO 36

miR150
mlR151

hsa·miR-148b'-AAGUUCUGUUAUACACUCAGGC ·SEQ ID NO 37
hsa-mlR-150-UCUCCCAACCCUUGUACCAGUG. sea 10 NO 36
hsa-m1R-151-5p·UCGAGGAGCUCACAGUCUAGU - SEQ ID NO 39
hsa-mJR-151-Jp-CUAGACUGAAGCUCCUUGAGG- preferred - SEQ 10 NO: 40

m<R181a
m<R181c

hsa-m<R-1S1a·AACAUUCAACGCUGUCGGUGAGU ·SEQ ID NO 41
hsa-mlR-161c-AACAUUCAACCUGUCGGUGAGU -SEQ ID NO 42
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Table 1: Small non-coding RN As suitable as blood markers
mi RNA
let7a
let7b
let7c
let7d
let7e
let7f
let7g
let7i

hsa-let-7a-UGAGGUAGUAGGUUGUAUAGUU - SEQ ID NO: 1
hsa-let-7b-UGAGGUAGUAGGUUGUGUGGUU - SEQ ID NO 2
hsa-let-7c-UGAGGUAGUAGGUUGUAUGGUU - SEQ ID NO: 3
hsa-let-7d-AGAGGUAGUAGGUUGCAUAGUU - SEQ ID NO: 4
hsa-let-7e-UGAGGUAGGAGGUUGUAUAGUU - SEQ ID NO: 5
hsa-let-7f-UGAGGUAGUAGAUUGUAUAGUU - SEQ ID NO: 6
hsa-let-7g-UGAGGUAGUAGUUUGUACAGUU - SEQ ID NO: 7
hsa-let-7i-UGAGGUAGUAGUUUGUGCUGUU - SEQ ID NO: 8

miR7

hsa-miR-7-UGGAAGACUAGUGAUUUUGUUGU - SEQ ID NO: 9

miR15a

hsa-miR-15a-UAGCAGCACAUAAUGGUUUGUG - SEQ ID NO: 10
hsa-miR-15b-UAGCAGCACAUCAUGGUUUACA- SEQ ID NO: 11
hsa-miR-16-UAGCAGCACGUAAAUAUUGGCG - SEQ ID NO: 12
hsa-miR-17-CAAAGUGCUUACAGUGCAGGUAG - SEQ ID NO: 13
hsa-miR-18a-UAAGGUGCAUCUAGUGCAGAUAG - SEQ ID NO: 14

miR15b

miR16
miR17
miR18a/b

miR1Ba·
miR19a
miR20a
miR25
miR26b
miR30b
miR30a/e5p

Human miRNAs

hsa-miR-18b-UAAGGUGCAUCUAGUGCAGUUAG ·SEQ ID NO: 15
hsa-miR-18a*-ACUGCCCUMGUGCUCCUUCUGG - SEQ ID NO: 16
hsa-miR-19a-UGUGCMAUCUAUGCAAAACUGA- SEQ ID NO: 17
hsa-m1R-20a-UAAAGUGCUUAUAGUGCAGGUAG ·SEQ ID NO: 18
hsa-miR-25-CAUUGCACUUGUCUCGGUCUGA - SEQ ID NO: 19
hsa-miR-26b-UUCMGUAAUUCAGGAUAGGU - SEQ ID NO: 20
hsa-miR-30b-UGUAAACAUCCUACACUCAGCU - SEQ ID NO: 21
hsa-miR-30a-UGUAAACAUCCUCGACUGGMG - SEQ ID NO: 22
hsa-miR-30e- UGUAMCAUCCUUGACUGGAAG - preferred - SEQ ID NO: 23

miR93
miR96
miR103

miR106a
miR106b
miR107

m!R126
miR126"
miR128
miR130a
miR148b

hsa-miR-93-CAAAGUGCUGUUCGUGCAGGUAG - SEQ ID NO: 24
hsa-miR-96-UUUGGCACUAGCACAUUUUUGCU - SEQ ID NO: 25
hsa-miR-103-AGCAGCAUUGUACAGGGCUAUGA- SEQ ID NO: 26
II hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA- SEQ ID NO: 29
hsa-miR-106a-AAAAGUGCUUACAGUGCAGGUAG - SEQ ID NO: 27
II hsa-miR-17 -CAAAGUGCUUACAGUGCAGGUAG • SEQ ID NO: 13
hsa-miR-106b-UMAGUGCUGACAGUGCAGAU ·SEQ ID NO: 28
hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA- SEQ ID NO: 29
hsa-miR-126-UCGUACCGUGAGUAAUAAUGCG - SEQ ID NO: 30
hsa-miR-12a·-cAUUAUUACUUUUGGUACGCG - SEQ ID NO: 31
has-miR-128-UCACAGUGMCCGGUCUCUUU - SEQ ID NO: 32
hsa-miR-130a-CAGUGCAAUGUUAAAAGGGCAU - SEQ ID NO: 33
hsa-miR-148a-UCAGUGCACUACAGMCUUUGU - SEQ ID NO 34
hsa-miR-148b-UCAGUGCAUCACAGAACUUUGU - SEQ ID NO: 35
hsa-miR-148a*-MAGUUCUGAGACACUCCGACU- SEQ ID NO: 36

miR150
miR151

hsa-miR-148b*-AAGUUCUGUUAUACACUCAGGC - SEQ ID NO: 37
hsa-miR-150-UCUCCCAACCCUUGUACCAGUG- SEQ ID NO: 38
hsa-miR-151-Sp-UCGAGGAGCUCACAGUCUAGU - SEQ ID NO: 39
hsa-miR-151-3p-CUAGACUGAAGCUCCUUGAGG - preferred - SEQ ID NO: 40

miR181a
miR181c

hsa-miR-181a-AACAUUCMCGCUGUCGGUGAGU - SEQ ID NO: 41
hsa-miR-181c-AACAUUCAACCUGUCGGUGAGU - SEQ ID NO: 42
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miR182
mlR182•
miR183
miR185
miR190
miR191
miR194
miR195
miR210
miR215
miR301

hsa-miR-182-UUUGGCAAUGGUAGAACUCACACU - SEQ ID NO: 43
hsa-miR-182°-UGGUUCUAGACUUGCCAACUA- SEQ ID NO: 44
hsa-miR-183-UAUGGCACUGGUAGAAUUCACU - SEQ ID NO: 45
hsa-miR-185-UGGAGAGAAAGGCAGUUCCUGA - SEQ ID NO: 46
hsa-miR-190-UGAUAUGUUUGAUAUAUUAGGU - SEQ ID NO: 47
hsa-miR-191-CAACGGAAUCCCAAAAGCAGCUG - SEQ ID NO: 48
hsa-miR-194-UGUAACAGCAACUCCAUGUGGA - SEQ ID NO 49
hsa-miR-195-UAGCAGCACAGAAAUAUUGGC - SEQ ID NO 50
hsa-miR-210-CUGUGCGUGUGACAGCGGCUGA - SEQ ID NO 51
hsa-miR-215-AUGACCUAUGAAUUGACAGAC- SEQ ID NO: 52
hsa-miR-301a-CAGUGCAAUAGUAUUGUCAAAGC- preferred - SEQ ID NO 53

miR324-3p
miR331

hsa-miR-301b-CAGUGCAAUGAUAUUGUCAAAGC - SEQ ID NO 54
hsa-miR-324-3p-ACUGCCCCAGGUGCUGCUGG - SEQ ID NO: 55
hsa-miR-331-3p-GCCCCUGGGCCUAUCCUAGAA- preferred - SEQ JD NO: 56

m1R324-3p
miR339

hsa-miR-331-5p-CUAGGUAUGGUCCCAGGGAUCC - SEQ ID NO 57
hsa-miR-324-Jp-ACUGCCCCAGGUGCUGCUGG - SEQ ID NO: 55
hsa-miR-339-Sp-UCCCUGUCCUCCAGGAGCUCACG - preferred - SEQ ID NO 58

miR340
miR363"
miR374
miR425
miR451
miR484
miR486

hsa-miR-339-3p-UGAGCGCCUCGACGACAGAGCCG - SEQ ID NO: 59
hsa-miR-340-UUAUAAAGCAAUGAGACUGAUU - SEQ ID NO: 60
hsa-miR-363·-CGGGUGGAUCACGAUGCAAUUU - SEQ ID NO: 61
hsa-miR-374-UUAUAAUACAACCUGAUAAGUG - SEQ ID NO: 62
hsa-miR-425-AAUGACACGAUCACUCCCGUUGA - SEQ ID NO: 63
hsa-miR-451-AAACCGUUACCAUUACUGAGUU - SEQ ID NO: 119
hsa-miR-484-UCAGGCUCAGUCCCCUCCCGAU - SEQ ID NO: 120
hsa-miR-486-Sp-UCCUGUACUGAGCUGCCCCGAG - preferred - SEQ ID NO: 64

miR500
miR545
miR548d

hsa-miR-486-3p-CGGGGCAGCUCAGUACAGGAU - SEQ ID NO: 65
hsa-miR-500-UAAUCCUUGCUACCUGGGUGAGA - SEQ ID NO: 66
hsa-miR-545-UCAGCAAACAUUUAUUGUGUGC - SEQ ID NO: 67
hsa-miR-548d-5p-AAAAGUAAUUGUGGUUUUUGCC - SEQ ID NO: 68

miR556

hsa-miR-548d-3p-CAAAAACCACAGUUUCUUUUGC - preferred - SEQ ID NO: 69
hsa-m1R-556-3p-AUAUUACCAUUAGCUCAUCUUU - SEQ ID NO 70

miR576

hsa-miR-556-Sp-GAUGAGCUCAUUGUAAUAUGAG - preferred - SEQ ID NO 71
hsa-m1R-576-3p-AAGAUGUGGAAAAAUUGGAAUC - SEQ ID NO: 72

miR579
miR580
miR581
miR590

hsa-miR-576-5p-AUUCUAAUUUCUCCACGUCUUU - preferred - SEQ ID NO: 73
hsa-miR-579-UUCAUUUGGUAUAAACCGCGAUU - SEQ ID NO: 74
hsa-miR-580-UUGAGAAUGAUGAAUCAUUAGG - SEQ ID NO 75
hsa-rniR-581-UCUUGUGUUCUCUAGAUCAGU - SEQ ID NO: 76
hsa-miR-590-5p-GAGCUUAUUCAUAAAAGUGCAG - preferred - SEQ ID NO: 77

mlR624

miR627
miR651
miR652
miR660
miR154•

miR607

hsa-miR-590-3p-UAAUUUUAUGUAUAAGCUAGU - SEQ ID NO: 78
hsa-miR-624-CACAAGGUAUUGGUAUUACCU - SEQ ID NO: 79
hsa-miR-627-GUGAGUCUCUAAGAAAAGAGGA ·SEQ ID NO: 80
hsa-miR-651-UUUAGGAUAAGCUUGACUUUUG - SEQ ID NO: 81
hsa-miR-652-AAUGGCGCCACUAGGGUUGUG - SEQ ID NO: 82
hsa-miR-660-UACCCAUUGCAUAUCGGAGUUG - SEQ ID NO: 83
hsa-miR-154·-AAUCAUACACGGUUGACCUAUU - SEQ ID NO: 84
hsa-miR-607-GUUCAAAUCCAGAUCUAUAAC - SEQ ID NO: 85
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Table 2: Small non-coding RNAs as marker for menstrual blood

miR27b
miR31
miR33
miR33b
miR95
miR106b
miR125a

hsa-miR-23b-AUCACAUUGCCAGGGAUUACC • SEQ ID NO: 87
hsa-miR-27b-UUCACAGUGGCUAAGUUCUGC - SEQ ID NO: 88
hsa-miR-31-AGGCAAGAUGCUGGCAUAGCU - SEQ ID NO: 89
hsa-miR-33 -GUGCAUUGUAGUUGCAUUGCA - SEQ ID NO: 90
hsa-miR-33b-GUGCAUUGCUGUUGCAUUGC ·SEQ ID NO. 91
hsa-miR-95-UUCAACGGGUAUUUAUUGAGCA. SEQ ID NO 92
hsa-miR-106b-UAAAGUGCUGACAGUGCAGAU ·SEQ ID NO: 28
hsa-miR·125a-3p-ACAGGUGAGGUUCUUGGGAGCC- SEQ ID NO: 93
hsa-miR-125a-5p-UCCCUGAGACCCUUUAACCUGUGA- preferred - SEQ ID

N0:94
miR125b
miR136
miR141
miR143
miR154
miR181b
miR24"
miR193b
miR199a

hsa-miR-125b-UCCCUGAGACCCUAACUUGUGA ·SEQ ID NO: 95
hsa-miR-136-ACUCCAUUUGUUUUGAUGAUGGA - SEQ ID NO: 96
hsa-miR-141-UAACACUGUCUGGUAAAGAUGG - SEQ ID NO: 97
hsa-miR-143-UGAGAUGAAGCACUGUAGCUC - SEQ ID NO: 98
hsa-miR-154-UAGGUUAUCCGUGUUGCCUUCG - SEQ ID NO: 99
hsa-miR-181b-AACAUUCAUUGCUGUCGGUGGGU - SEQ ID NO: 100
hsa - miR24' - UGCCUACUGAGCUGAUAUCAGU- SEQ ID NO: 101
hsa-miR-193b-AACUGGCCCUCAAAGUCCCGCU - SEQ ID NO: 102
hsa-miR-199a-3p-ACAGUAGUCUGCACAUUGGUUA- SEQ ID NO: 103
hsa-miR-199a-5p-CCCAGUGUUCAGACUACCUGUUC- preferred - SEQ ID NO

104
m1R199b

miR200b
miR200c
miR203
mlR218
miR223
miR337

miR377
miR3B2
miR412
mlR423

mlR425-3p
miR451
miR484
miR384
miR382
miR429
miR431
miR452
miR452°
miR494

hsa-miR-199b-5p-CCCAGUGUUUAGACUAUCUGUUC- preferred - SEQ ID NO:
105
hsa-miR-199b-3p-ACAGUAGUCUGCACAUUGGUUA- SEQ ID NO. 103
hsa-miR-200b-UAAUACUGCCUGGUAAUGAUGA - SEQ ID NO: 106
hsa-miR-200c-UAAUACUGCCGGGUAAUGAUGGA ·SEQ ID NO: 107
hsa-miR-203-GUGAAAUGUUUAGGACCACUAG - SEQ ID NO: 108
hsa-miR-218-UUGUGCUUGAUCUAACCAUGU - SEQ ID NO: 109
hsa-miR-223-UGUCAGUUUGUCAAAUACCCCA - SEQ ID NO 110
hsa-miR-337-3p-CUCCUAUAUGAUGCCUUUCUUC-preferred- SEQ ID NO: 111
hsa-miR-337-5p-GAACGGCUUCAUACAGGAGUU - SEQ ID NO: 112
hsa-miR-377-AUCACACAAAGGCAACUUUUGU - SEQ ID NO: 113
hsa-miR-382-GAAGUUGUUCGUGGUGGAUUCG - SEQ ID NO 114
hsa-miR-412-ACUUCACCUGGUCCACUAGCCGU - SEQ ID NO: 115
hsa-m1R-423-3p-AGCUCGGUCUGAGGCCCCUCAGU - preferred - SEQ ID NO·
116
hsa-miR-423-5p-UGAGGGGCAGAGAGCGAGACUUU ·SEQ ID NO: 117
hsa-miR-425-3p - UAGUGCAAUAUUGCUUAUAGGGU ·SEQ ID NO. 118
hsa-miR-451-AAACCGUUACCAUUACUGAGUU ·SEQ ID NO: 119
hsa-miR-484-UCAGGCUCAGUCCCCUCCCGAU ·SEQ ID NO: 120
hsa-miR-384-AUUCCUAGAAAUUGUUCAUA ·SEQ ID NO: 121
hsa-miR-382-GAAGUUGUUCGUGGUGGAUUCG - SEQ ID NO· 114
hsa-miR-429-UAAUACUGUCUGGUAAAACCGU · SEQ ID NO: 122
hsa-miR-431-UGUCUUGCAGGCCGUCAUGCA- SEQ ID NO: 123
hsa-miR-452-AACUGUUUGCAGAGGAAACUGA - SEQ ID NO: 124
hsa-mlR-452·-cucAUCUGCAAAGAAGUAAGUG - SEQ ID NO: 125
hsa-miR-494-UGAAACAUACACGGGAAACCUC- SEQ ID NO: 126
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miR497
miR517*
miR611
miR633
miR637
miR641
miR648
miR211
miR216

hsa-miR-497-CAGCAGCACACUGUGGUUUGU - SEQ ID NO: 127
hsa-miR-517'-CCUCUAGAUGGAAGCACUGUCU - SEQ ID NO: 128
hsa-miR-611-GCGAGGACCCCUCGGGGUCUGAC - SEQ ID NO: 176
hsa-miR-633-CUAAUAGUAUCUACCACAAUAAA- SEQ ID NO: 129
hsa-miR-637 -ACUGGGGGCUUUCGGGCUCUGCGU - SEQ ID NO: 130
hsa-miR-641-AAAGACAUAGGAUAGAGUCACCUC ·SEQ ID NO: 131
hsa-miR-648-AAGUGUGCAGGGCACUGGU - SEQ ID NO: 132
hsa-miR-211-UUCCCUUUGUCAUCCUUCGCCU ·SEQ ID NO: 133
hsa-miR-216a-UAAUCUCAGCUGGCAACUGUGA - preferred ·SEQ ID NO: 192

miR369-5p
miR376a/b

hsa-miR-216b-AAAUCUCUGCAGGCAAAUGUGA - SEQ ID NO: 191
hsa-miR-369-Sp-AGAUCGACCGUGUUAUAUUCGC - SEQ ID NO: 134
hsa-miR-376a-AUCAUAGAGGAAAAUCCACGU - SEQ ID NO: 135

miR379
miR489
mlR507

hsa-miR-376b-AUCAUAGAGGAAAAUCCAUGUU - SEQ ID NO: 136
hsa-miR-379-UGGUAGACUAUGGAACGUAGG - SEQ ID NO: 137
hsa-miR-489-GUGACAUCACAUAUACGGCAGC - SEQ ID NO: 138
hsa-miR-507-UUUUGCACCUUUUGGAGUGAA- SEQ ID NO: 139

FIG. 2(continued)
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Table 3: Small non-coding RNAs as marker for semen
mi~H1E

Human'miRNAs , • . · ·.

mlR10b
miR99a
miR100
miR135a
miR135b
miR149
mlR204
miR449

hsa-miR-99a-AACCCGUAGAUCCGAUCUUGUG - SEO ID NO: 141
hsa-miR-100-AACCCGUAGAUCCGAACUUGUG - SEQ ID NO: 142
hsa-m1R-135a-UAUGGCUUUUUAUUCCUAUGUGA- SEQ ID NO 143
hsa-m1R-135b-UAUGGCUUUUCAUUCCUAUGUGA- SEQ ID NO: 144
hsa-miR-149-UCUGGCUCCGUGUCUUCACUCCC - SEQ ID NO: 145
hsa-mlR-204-UUCCCUUUGUCAUCCUAUGCCU - SEQ ID NO: 146
hsa-miR-449a-UGGCAGUGUAUUGUUAGCUGGU- preferred - SEO ID NO: 147

miR508

.

.v ·

. .

hsa-miR-10b~UACCCUGUAGAACCGAAUUUGUG -·SEQ

•.

IDNO: 140 ..

hsa-miR-449b-AGGCAGUGUAUUGUUAGCUGGC - SEQ ID NO 148
hsa-miR-508-3p-UGAUUGUAGCCUUUUGGAGUAGA - preferred - SEQ ID NO:
149

miR555
miR509

hsa-miR-508-5p-UACUCCAGAGGGCGUCACUCAUG • SEQ ID NO: 150
hsa-miR-513-UUCACAGGGAGGl)GUCAU - SEQ ID NO: 151
hsa-miR-517a-AUCGUGCAUCCCUUUAGAGUGU - SEQ ID NO 152
hsa-miR-518!'-CUCUAGAGGGAAGCACUUUCUC - SEQ ID NO: 153
hsa-m1R-519d·CAAAGUGCCUCCCUUUAGAGUG - SEO ID NO: 154
hsa-miR-519e-AAGUGCCUCCUUUUAGAGUGUU - SEQ ID NO: 155
hsa-miR-520a-3p-AAAGUGCUUCCCUUUGGACUGU - SEQ ID NO: 156
hsa-miR-520a 0 -AAAGUGCUUCCCUUUGGACUGU - SEQ ID NO: 156
hsa-miR-520e-AAAGUGCUUCCUUUUUGAGGG- SEQ 10 NO: 157
hsa-miR-520g-ACAAAGUGCUUCCCUUUAGAGUGU - SEQ ID NO: 158
II hsa-miR-520h-ACAAAGUGCUUCCCUUUAGAGU - SEQ ID NO: 159
hsa-miR-555-AGGGUAAGCUGAACCUCUGAU - SEQ ID NO: 224
hsa-miR-509-3-5p-UACUGCAGACGUGGCAAUCAUG - SEQ ID NO 160

mlR514
miR515-5p
miR516-3p
miR517"
miR518a

hsa-miR-509-3p-UGAUUGGUACGUCUGUGGGUAG - preferred - SEQ ID NO:
161
hsa-miR-514-AUUGACACUUCUGUGAGUAGA ·SEQ ID NO. 162
hsa-miR-515-5p-UUCUCCAAAAGAAAGCACUUUCUG - SEQ ID NO: 204
has-miR-516a-3p-UGCUUCCUUUCAGAGGGU - SEQ ID NO: 163
hsa-miR-517'-CCUCUAGAUGGAAGCACUGUCU - SEQ ID NO: 128
hsa-miR-518a-5p-CUGCAAAGGGAAGCCCUUUC - SEQ ID NO: 164

miR518c
miR518e
miR519e"
m1R520d

hsa-miR-518a-3p-GAAAGCGCUUCCCUUUGCUGGA- preferred - SEQ ID
N0:165
hsa-miR-518c-CAAAGCGCUUCUCUUUAGAGUGU - SEQ ID NO: 166
hsa-miR-518e·AAAGCGCUUCCCUUCAGAGUG - SEQ ID NO: 167
hsa-m1R-519e 0 -UUCUCCAAAAGGGAGCACUUUC - SEQ ID NO 168
hsa-m1R-520d-5p-CUACAAAGGGAAGCCCUUUC - SEQ ID NO: 169

miR521
miR524
miR524*
miR525"
miR526a
miR549
miR558
miR578
miR611

hsa-miR-520d-3p-AAAGUGCUUCUCUUUGGUGGGU - SEQ ID NO: 170
hsa-miR-521-AACGCACUUCCCUUUAGAGUGU - SEQ ID NO: 182
hsa-miR-524-3p-GAAGGCGCUUCCCUUUGGAGU ·SEQ ID NO: 171
hsa-miR-524-Sp-CUACAAAGGGAAGCACUUUCUC - SEQ ID NO: 172
hsa-miR-525-3p-GAAGGCGCUUCCCUUUAGAGCG - SEQ ID NO: 209
hsa-miR-526a-CUCUAGAGGGAAGCACUUUCUG - SEQ ID NO: 173
hsa-miR-549-UGACAACUAUGGAUGAGCUCU- SEQ ID NO: 174
hsa-miR-558-UGAGCUGCUGUACCAAAAU ·SEQ ID NO 225
hsa-miR-578-CUUCUUGUGCUCUAGGAUUGU - SEQ ID NO: 175
hsa-miR-611-GCGAGGACCCCUCGGGGUCUGAC- SEQ ID NO: 176

miR513
miR517a
miR518f*
miR519d
m1R519e
miR520a
miR52oa•
miR520e
miR520g/h

FIG. 3
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Table 4: Small non-coding RNAs as marker for vaginal secretions

miR34a
miR124a
miR195
mlR372
miR502

mlRS21

miR568
miR575

hsa-miR-34a-UGGCAGUGUCUUAGCUGGUUGU - SEQ ID NO: 177
has-miR-124a-UAAGGCACGCGGUGAAUGCC - SEQ ID NO: 178
hsa-miR-195-UAGCAGCACAGAAAUAUUGGC- SEQ ID NO: 50
hsa-miR-372-AAAGUGCUGCGACAUUUGAGCGU - SEQ ID NO: 179
hsa-miR-502-3p-AAUGCACCUGGGCAAGGAUUCA - SEQ ID NO: 180
hsa-miR-502-5p-AUCCUUGCUAUCUGGGUGCUA- preferred - SEQ ID NO: 181
hsa-miR-521-AACGCACUUCCCUUUAGAGUGU - SEQ ID NO: 182
hsa-miR-568-AUGUAUAAAUGUAUACACAC - SEQ ID NO: 183
hsa-miR-575-GAGCCAGUUGGACAGGAGC - SEQ ID NO: 184

FIG. 4
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Table 5: Small non-coding RNAs as marker for salvia

:miml~L~'-···· : ,;HJ:J~ll~mIRN!\l'.Gff~~i ';J;;~·~· ;;;;;Jt':, ;Z .~~: .

·.

miR10a
miR137
miR205
miR206
miR208

;,,.,LctL. - . ' .:.~~~E~.
hsa-miR-10a-UACCCUGUAGAUCCGAAUUUGUG - SEQ ID NO 185
hsa-miR-137-UUAUUGCUUAAGAAUACGCGUAG- SEQ ID NO: 186
hsa-miR-205-UCCUUCAUUCCACCGGAGUCUG - SEQ ID NO: 187
hsa-miR-206-UGGAAUGUAAGGAAGUGUGUGG- SEQ ID NO: 188
hsa-miR-208a-AUAAGACGAGCAAAMGCUUGU - preferred - SEQ ID NO: 189

miR216

hsa-miR-208b-AUAAGACGAACAAAAGGUUUGU - SEQ ID NO: 190
hsa-miR-216b-AAAUCUCUGCAGGCAAAUGUGA - SEQ ID NO: 191

miR302a
miR302b'

hsa-miR-216a-UAAUCUCAGCUGGCAACUGUGA- preferred - SEQ ID NO: 192
hsa-miR-302a-UAAGUGCUUCCAUGUUUUGGUGA - SEQ ID NO: 193
hsa-miR-302b -ACUUUAACAUGGAAGUGCUUUC - SEQ ID NO: 194

miR302c
miR302c"
miR346
miR383
miR498
miR499

hsa-miR-302c-UAAGUGCUUCCAUGUUUCAGUGG- SEQ ID NO: 195
hsa-m1R-302c -UUUAACAUGGGGGUACCUGCUG - SEQ ID NO: 196
hsa-miR-346-UGUCUGCCCGCAUGCCUGCCUCU - SEQ ID NO. 197
hsa-miR-383-AGAUCAGAAGGUGAUUGUGGCU - SEQ ID NO: 198
hsa-miR-498-UUUCAAGCCAGGGGGCGUUUUUC - SEQ ID NO 199
hsa-miR-499-5p-UUAAGACUUGCAGUGAUGUUU - preferred - SEQ ID NO: 200

miR509

hsa-miR-499-3p-AACAUCACAGCAAGUCUGUGCU - SEQ ID NO: 201
has-miR-509-3p-UGAUUGGUACGUCUGUGGGUAG - SEQ ID NO: 202

miR510
mlR515-5p
miR518c•
miR519b

hsa-miR-510-UACUCAGGAGAGUGGCAAUCAC - SEQ ID NO: 203
hsa-miR-515-5p-UUCUCCAAAAGAAAGCACUUUCUG- SEQ ID NO: 204
hsa-miR-518c 0 -UCUCUGGAGGGAAGCACUUUCUG- SEQ ID NO: 205
hsa-miR-519b-3p-AAAGUGCAUCCUUUUAGAGGUU - preferred - SEQ ID NO: 206

miR520d

hsa-miR-5191:>-Sp-CUCUAGAGGGAAGCGCUUUCUG - SEQ ID NO 207
hsa-miR-520d-3p-AAAGUGCUUCUCUUUGGUGGGU - SEQ ID NO: 170

miR525

hsa-miR-520d-5p-CUACAAAGGGAAGCCCUUUC - SEQ ID NO: 169
hsa-miR-525-5p-CUCCAGAGGGAUGCACUUUCU - preferred • SEQ ID NO: 208

miR526b
miR548b

hsa-miR-525-3p-GAAGGCGCUUCCCUUUAGAGCG - SEQ ID NO: 209
has-miR-526b-CUCUUGAGGGAAGCACUUUCUGU - SEQ ID NO: 210
hsa-miR-548b-3p-CAAGAACCUCAGUUGCUUUUGU - preferred - SEQ ID NO: 211

mfR551a
miR553
rniR577
miR600
miR604
miR606
miR643
miR647
miR658
miR802
miR516-5p
mlR555
miR558
miR569
mlR587

hsa-miR-5481:>-Sp-AAAAGUAAUUGUGGUUUUGGCC ·SEQ ID NO: 212
hsa-miR-551a-GCGACCCACUCUUGGUUUCCA- SEQ ID NO: 213
hsa-miR-553-AAAACGGUGAGAUUUUGUUUU - SEQ ID NO: 214
hsa-mlR-577-UAGAUAAAAUAUUGGUACCUG - SEQ ID NO 215
hsa-miR-600-ACUUACAGACAAGAGCCUUGCUC - SEQ ID NO: 216
hsa-miR-604-AGGCUGCGGAAUUCAGGAC - SEQ ID NO 217
hsa-miR-606-AAACUACUGAAAAUCAAAGAU - SEQ ID NO: 218
hsa-miR-643-ACUUGUAUGCUAGCUCAGGUAG- SEQ ID NO: 219
hsa-miR-647-GUGGCUGCACUCACUUCCUUC- SEQ ID NO: 220
hsa-rniR-658-GGCGGAGGGMGUAGGUCCGUUGGU - SEQ ID NO: 221
hsa-miR-802-CAGUAACAAAGAUUCAUCCUUGU - SEQ ID NO: 222
hsa-miR-516a-5p-UUCUCGAGGAAAGAAGCACUUUC - SEQ ID NO: 223
hsa-miR-555-AGGGUAAGCUGAACCUCUGAU • SEQ ID NO: 224
hsa-miR-558-UGAGCUGCUGUACCAAAAU - SEQ ID NO: 225
hsa-miR-569-AGUUAAUGAAUCCUGGAAAGU - SEQ ID NO: 226
hsa-miR-587-UUUCCAUAGGUGAUGAGUCAC- SEQ ID NO: 227

0

0
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METHOD FOR DETERMINING THE ORIGIN
OF A SAMPLE

identify the species of origin. Therefore these methods are
costly not only in the time and labor required fortheir completion, but also in terms of the amount of sample consumed
during the performance of each assay. While these conventional methods can confirm the presence of human blood and
semen, none of the routinely used serological and immunological tests can definitely identify the presence of human
saliva or vaginal secretions. With the large volume of cases
that operational crime laboratories are faced with processing
every year, a significant amount of the total time spent on an
individual case can be devoted solely to the screening of
evidentiary items for the presence of biological materials.
The inability to positively confirm the presence of certain
biological fluids, the consumption of valuable samples and
the time and labour required has resulted in a trend to bypass
conventional body fluid identification methods and proceed
straight to the analysis of DNA present in forensic samples.
There are several disadvantages to bypassing the body fluid
identification step during bio-molecular forensic analysis.
First, the analytical methods used to analyze DNA are considerably more expensive than basic serological testing. A
second disadvantage of the disuse of body fluid identification
methods is that often the identification of the biological material present is crucial to the investigation and prosecution of
the case.
The routine use of body fluid identification methods prior
to DNA analysis awaits the development of suitable molecular genetics based methods that are fully compatible with the
current DNA analysis pipeline. In order for any new body
fluid assay to be suitable for forensic casework it must demonstrate a high degree of specificity for each body fluid,
permit parallel analysis of the different biological fluids, be
completed in a timely and labour efficient manner and must
be sufficiently sensitive.
It is thus the object of the present invention to provide a
method which allows determining the nature of a sample,
such as a forensic sample.

CROSS-REFERENCE TO RELATED
APPLICATIONS
The present application is a U.S. National Stage Application under35 U.S.C. §371 oflntemational PatentApplication
No. PCT/EP2009/005254, filed Jul. 20, 2009, which claims
benefit of U.S. Provisional Patent Application No. 61/082,
056, filed Jul. 18, 2008.
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SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted via EFS-Web and is hereby incorporated
by reference in its entirety. Said ASCII copy, created on Jan.
18, 2011, is named Sequence_listing.txt and is 33, 798 byte in
size.
The present application pertains to methods and kits for
determining the nature (e.g. origin) of a sample, e.g. a body
fluid. The teaching of the present application is particularly
useful in the field of human identity testing, paternity testing
or forensic science (forensics).
The application of DNA technology to the biological evidence in criminal casework has revolutionized forensic science. The ability to identify, with a high degree of certainty, a
suspect in violent crimes now routinely provides valuable
leads to criminal investigators worldwide, often in circumstances where there are no eyewitnesses. Forensic DNA technology or STR-typing is a very sensitive and universally
accepted scientific technique. STRs are small DNA regions
that contain DNA segments that repeat several times in tandem. Repeated sequences are a fundamental feature of
genomes and play an important role in genomic fingerprinting (for review see Jobling and Gill, Nature Reviews in
Genetics, Vol. 5, pp 739; 2004).
Human identity DNA testing involves generating information on the size and number of certain repetitive sequences.
This information resembles the unique pattern of a fingerprint
and is thus often referred to as the "genetic fingerprint" of a
human individual. Genetics fingerprints may be compared
with each other in a database system and allow for positive
identification of an individual.
However, genetic fingerprints do not reveal any information on the physical appearance of the human donor--except
for the sex---or the specific nature and origin of the human
sample. However, such information is very useful in criminal
investigation as it can make a decisive difference whether a
sample obtained from the clothing of a sexual assault victim
is a droplet of sperm or saliva, or whether blood sampled from
some female underwear is peripheral or menstrual blood.
Conventional methods for the identification of different
body fluids like blood, semen and saliva from biological
stains involve immunological or enzymatic detection of certain proteins, which are characteristic for the respective
sample. However, these technologies (e.g. ELISA, lateral
flow chromatography) are often not sensitive enough for
forensic investigation as proteins camiot be amplified and
forensic stains often contain only minute amounts of materials.
Typically, such conventional methods for body fluid stain
analysis are carried out in a serial mamier, with a portion of
the stain being tested for only one body fluid at a time.
Frequently multiple tests are required to first presumptively
identify the presence of biological fluids followed by additional testing in order to confirm the presence of the fluid or
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FIG. 1 shows Table 1 which depicts suitable miRNAs
which are useful markers for blood.
FIG. 2 shows Table 2 which depicts suitable miRNAs
which are useful markers for menstrual blood.
FIG. 3 shows Table 3 which depicts suitable miRNAs
which arc useful markers for semen.
FIG. 4 shows Table 4 which depicts suitable miRNAs
which are useful markers for vaginal secretions
FIG. 5 shows Table 5 which depicts suitable miRNAs
which are useful markers for saliva.
FIG. 6 shows the results of a miRNA candidate screening
using pooled body fluid samples.
FIG. 7A-7E show the development of 2-1) miRNA body
fluid identification assays.
FIG. 8 shows the stability of miRNA expression even in
environmentally compromised.
FIG. 9 shows the generation of mature miRNAs according
to one assumed embodiment.
According to one embodiment, a method for determining
the nature of a sample is provided, wherein the presence or
absence of at least one marker small non-coding RNA in the
sample is detected. The detection of a respective marker small
non-coding RNA allows the identification of the nature of the
sample, such as e.g. its origin or type. The analysis/detection
of the expression of at least one small non-coding RNA is
advantageous over conventional detection methods which
e.g. target mRNA, which is likely to be more susceptible to

US 8,936,909 B2
3

4

degradation and expected to be less stable due to its larger
size. It is also advantageous over the detection of marker
proteins due to the reasons outlined above. However, respective methods can also be used in combination with the method
of the present invention.
Several small non-coding RNAs (ncRNAs) are known in
the prior art. They comprise infrastructural ncRNAs such as,
for example, tRNAs, rRNAs, spliceosomal uRNAs or snRNAs and the common snoRNAs. Both translation and splicing require core infrastructural RNAs not only for sequencespecific recognition of RNA substrates, but also for the
catalytic process itself. A further category of small non-coding RNAs comprises small regulatory ncRNAs such as snoRNAs and miRNAs/siRNAs.
snoRNAs generally range from 50 to 300 nucleotides in
length and guide the side-specific modification of nucleotides
and target RNAs via short regions of base paring. There are
two major classes, the box CID snoRNAs which guide 2'-0ribose-metylation and the box HI ACA snoRNAs which guide
pseudouridylation of target RNAs. At least some snoRNAs
exhibit tissue-specific and developmental regulation and/or
imprinting, indicative of a regulatory function.
miRNAs and siRNAs are short, approximately less than 30
and usually around 22 nucleotides long RNA molecules
derived either from hairpin or double stranded RNA precursors. Details of miRNA and siRNA biology and their biochemistry are known in the prior art. miRNAs suppress translation via non-perfect pairing with target mRNAs-usually
involving a seed pairing ofjust 6-8 nucleotides in length or (as
with siRNAs) cause degradation of target RNAs via the RISC
complex in the case of perfect complementarily with the
target site-the phenomenon known as RNAi. It is estimated
that approximately 113 of human protein-coding genes are
controlled by miRNAs. In addition, siRNAs derived from
repeats participate in the establishment of silenced (heterochromatic) chromatin, as well as in other aspects of chromosome dynamics. miRNAs are derived from the intrans and
exons of both protein-coding and non-coding transcripts that
are synthesised by RNA polymerase II. It has recently been
shown that a number of mammalian miRNAs are derived
from repeats, mainly various transposons. Some miRNAs
also appear to be derived from processed pseudo genes.
An overview over small non-coding RNAs, their structure
and function is described in John S. Mattick and Igor V.
Makunin: Non-coding RNA, Human Molecular Genetics
2006, Volume 15, review issue 1Rl7-R29, herein fully incorporated by reference.
According to one embodiment the small non-coding RNA
is a miRNA. In the last few years, the identification of
microRNA (miRNA) and the recognition ofits important role
in regulation of gene expression have led to increasing interest in the identification and characterization of miRNAs
(Cummins, J.M. andVelculescu, V. E. (2006) Implications of
micro-RNA profiling for cancer diagnosis. Oncogene 25,
6220; microRNAs supplement (2006) Nature Genetics 38,
6s; Kloosterman, W. P. and Plasterk, R. H. (2006) The diverse
functions of microRNAs in animal development and disease.
Dev. Cell 11, 441. A growing body of evidence suggests that
miRNAs play a role in many diverse biological processes
such as development, differentiation, and apoptosis. Misregulation of miRNA expression is reported to be associated
with several cancers and other diseases. MicroRNAs (miRNAs) are small non-coding RNAs, which usually have a
length of less than 30 nt, usually around 21 to 22 nt. The
generation ofmiRNAs is also described in FIG. 9.
miRNAs and other small non-coding RNAs such as snoRNAs or piRNAs are ideal assay targets for identifying the

nature of a sample, e.g. in forensic testing due to several
reasons. Because of their small size they are generally
expected to be more stable than larger RNA species and in
particular mRNA. In addition they are typically expressed at
very high rates. Thus, they potentially can also be recovered
from older samples what is of particular importance in the
field of forensics. Furthermore, their regulatory function in
gene expression during human development and tissue differentiation suggests the potential for identification of specific miRNA species that are indicative of the nature of a
sample or even the donor's physical status such as age or
health. To date more than 500 different individual miRNA
and other small RNAs have been identified in humans. The
identification of miRNAs which are specifically expressed in
a particular sample type provides a valuable marker for
sample typing.
According to one embodiment, the presence or absence of
at least two marker small-non-coding RNAs in the sample is
detected in order to determine the nature of the sample. To
characterise the sample type (e.g. to determine whether a
sample is semen or saliva) by using at least two sample
specific markers provides more security during testing and
allows a more reliable interpretation/control of the results.
A specifically suitable marker small non-coding RNA has
at least one of the following characteristics:
a. It is expressed in the particular sample for which the
small non-coding RNA serves as marker;
b. it shows a discriminating/differential expression pattern
in a particular type of sample compared to other sample
types;
c. it is specifically expressed in a particular sample type;
and/or
d. it is expressed in higher abundance in a particular sample
type.
A respective expression pattern which is characteristic for
a particular sample type and differs from the expression pattern in other (either all, or at least some) sample types ensures
sufficient specificity for the sample type for which the respective small non-coding RNA is used as a marker. Appropriate
differentiation of the expression in the particular type of
sample compared to other samples is important in order to
enhance the specificity of the determination method. It is
advantageous to use a marker small non-coding RNA which
is expressed in the particular sample. This, as the detection of
an expression ensures that the assay worked properly. In case
a marker small non-cording RNA is used whose characteristic
is that it is not expressed in a certain sample type, there is
always a certain risk/doubt that the method/assay did not
work properly which would need to be ensured by using
appropriate controls. The use of a high-abundance small noncoding RNA over a low-abundance small non-coding RNA is
generally preferred, as the expression of a high-abundance
marker is easier to detect.
Typical sample types that play an important role in particular in the field of forensics are e.g. blood, menstrual blood,
semen, vaginal secret and saliva. The method of the present
invention allows a reliable identification/determination of the
type of the respective sample by detecting/analysing the
expression pattern of respective marker small non-coding
RNAs. The detection of the expression of a specific marker or
a certain marker profile characteristic for the specific sample
allows the identification of the nature/origin of the sample
(e.g. whether it is semen or saliva). It is also within the scope
of the present invention to detect the presence or absence of a
plurality of small non-coding RNAs indicative as markers for
a plurality of different sample types, and determining the
nature of the sample based on the obtained expression profile
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for the respective markers. E.g. in case a sample is collected
at a forensic scene that could be blood, one could simultaneously or consecutively perform the method of the present
application by analysing the expression of marker small noncoding RNAs for blood and menstrual blood. Depending on
the obtained expression profile, one would obtain the information whether the collected sample is peripheral blood or
menstrual blood. The principle is also valid for other sample
types such as the ones mentioned above. The marker small
non-coding RNAs for different tissues may also be tested in
parallel and thus in one assay thereby allowing the typing of
the unidentified sample.
For detecting the marker small non-coding RNA in the
sample, any detection method can be used. It is preferred that
the detection method also allows a quantification of the
detected marker small non-coding RNA in the sample.
Hence, the detection is preferably quantitative. Non-limiting
examples of suitable detection methods are amplification,
PCR, real time PCR, e.g. using SybrGreen or probes, isotherma! amplification reactions, sequencing reactions, in particular pyrosequencing and massive parallel high throughput
sequencing (for example 454 sequencing, Applied Biosystems SOLID which also allows a quantification), detection
based on hybridisation techniques, e.g. via microarrays,
chips, bead arrays, functionalised surfaces, e.g. using microtiter plates, and detection via high resolution melt curve
analysis. The detection may comprise the use of labelled
probes/oligonucleotides, for example fluorescently labelled
oligonucleotides or amplification products. Other detectable
signals are based e.g. on chemiluminescence, radioactivity or
electrochemical processes. Several suitable detection methods are known in the prior art that can be used in conjunction
with the present invention which thus do not need to be
described in detail herein. Suitable methods are also
described in WO 2008/020008, herein incorporated by reference.
According to one embodiment, at least one small noncoding RNA is detected which comprises or consists of a
sequence selected from the group of small non-coding RNAs
listed in Table 1 (see FIG. 1) or is an isoform thereof (having
no more than 5, preferably no more than 3 or more preferred
no more than 2 base changes) or is derived from the same
premiRNA as the respective small non-coding RNAs listed in
Table 1 (see FIG. 1), as a marker for blood, in particular
peripheral blood. The respective miRNAs are specifically/
differentially expressed in blood samples and are thus suitable markers for determining/identifying an unknown sample
as a blood sample. Suitable sequence specific oligonucleotides and probes that are useful for amplifying and/or detecting the corresponding marker miRNAs can be designed
applying known principles e.g. based on the shown sequence
of the miRNA; sequence specific oligonucleotides and probes
should be at least 80% homologous, preferably at least 90%
complementary to the target sequence to allow sequence specific detection. It is advantageous that at least two small
non-coding RNAs are selected from the following group of
small non-coding RNAs as markers for blood:

-continued

Let7i
miR15a
miR15b
miR16
miR106a
miR106b
miR126
miR182
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miR182*
miR185
miR190
miR195
miR374
miR451
miR545
miR624
miR627
miR154*
miR607

It was demonstrated in extensive experiments by the inventors that the respective miRNAs are useful markers for blood,
particularly peripheral blood, which thus allow the secure
identification/determination of an unknown sample as a
respective blood sample. Particularly advantageous are the
use of Let7i, miR16, miR451, and/or miR15b as specific
markers. Preferably, at least miR451 andmiR16 are used as a
marker pair respectively marker combination for typing
peripheral blood samples.
In addition or alternatively, at least one small non-coding
RNA is detected which comprises or consists of a sequence
selected from the group of small non-coding RNAs listed in
Table 2 (see FIG. 2) or is an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no more
than 2 base changes) or is derived from the same premiRNA
as the respective small non-coding RNAs listed in Table 2 (see
FIG. 2), as a marker for menstrual blood. The respective
miRNAs are specifically/differentially expressed in blood
samples and in particular in menstrual blood samples and are
thus suitable markers for determining/identifying an
unknown sample as a menstrual blood sample. Suitable
sequence specific oligonucleotides and probes that are useful
for amplifying and/or detecting the corresponding marker
miRNAs can be designed applying known principles e.g.
based on the shown sequence of the miRNA; sequence specific oligonucleotides and probes should be at least 80%
homologous, preferably more than 90% complementary to
the target sequences to allow sequence specific detection. It is
advantageous that at least two small non-coding RNAs are
selected from the following group of small non-coding RNAs
as markers:
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miR23a!b
miR33
miR95
miR106b
miR154
miR218
miR369-5p
miR377
miR412
miR423
miR425-3p
miR451
miR452
miR452*
miR484
miR494
miR648
miR369-5p
miR507
miR648

Particularly suitable are the detection of the following
miRNAs as markers for menstrual blood: miR451, miR423,
miR484, miR412, miR425-3p and/or miR452*. It was demonstrated in extensive experiments by the inventors that the
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respective miRNAs are useful markers for menstrual blood
which thus allow the secure identification/determination of
an unknown sample as a menstrual blood sample even compared to a peripheral blood sample. Particularly suitable is the
use of at least miR412 and miR451 as marker pair respectively combination for typing menstrual blood samples. The
respective markers also allow a differentiation between menstrual blood and peripheral blood samples.
The detection of menstrual blood markers in combination
with general and/or peripheral blood markers (see above) is
particularly useful for a blood/menstrual blood assay. As the
menstrual blood markers also show a differential expression
pattern in peripheral blood compared to menstrual blood, they
can also be used in order to distinguish peripheral blood from
menstrual blood samples.
In addition or alternatively, at least one small non-coding
RNA is detected which comprises or consists of a sequence
selected from the group of small non-coding RNAs listed in
Table 3 (see FIG. 3) or is an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no more
than 2 base changes) or is derived from the same premiRNA
as the respective small non-coding RNAs listed in Table 3 (see
FIG. 3), as a marker for semen. The respective miRNAs are
specifically/differentially expressed in semen samples and
are thus suitable markers for determining/identifying an
unknown sample as a semen sample. Suitable sequence specific oligonucleotides and probes that are useful for amplifying and/or detecting the corresponding marker miRNAs can
be designed applying known principles e.g. based on the
shown sequence of the miRNA; sequence-specific oligonucleotides and probes should be at least 80% homologous,
preferably at least 90% complementary to the target
sequences to allow sequence-specific detection. It is advantageous that at least two small non-coding RNAs are selected
from the following group of small non-coding RNAs as markers for semen:

than 5, preferably no more than 3 or more preferred no more
than 2 base changes) or is derived from the same premiRNA
as the respective small non-coding RNAs listed in Table 4 (see
FIG. 4), as a marker for vaginal secretions. The respective
miRNAs are specifically/differentially expressed in vaginal
secretion samples and are thus suitable markers for determining/identifying an unknown sample as a vaginal secretion
sample. Suitable sequence specific oligonucleotides and
probes that are useful for amplifying and/or detecting the
corresponding marker miRNAs can be designed applying
known principles e.g. based on the shown sequence of the
miRNA, oligonucleotides shall be at least 80% homologous,
preferably at least 90% complementary to the target
sequences to allow sequence specific detection. It is advantageous that at least two small non-coding RNAs are selected
from the following group of small non-coding RNAs as markers for vaginal secretion samples:

miRlOb
miR99a
miR135a
miR135b
miR204
miR508
miR513
miR517a
miR518f*
miR519d
miR520a*
miR520g/h
miR514
miR518c
miR518e
miR524*
miR611

It was demonstrated in extensive experiments by the inventors that the respective miRNAs are particularly useful markers for semen which thus allow the secure identification/
determination of an unknown sample as a semen sample.
Particularly suitable are the detection of the following miRNAs as markers for semen: miRlOb, miR135b, miR517a,
miR508, miR514, miR520g/h and/or miR204. Particularly
suitable is the use of at least miR135b and miRl Ob as marker
pair respectively marker combination for typing/identifying
semen samples.
Alternatively or additionally, at least one small non-coding
RNA is detected which comprises or consists of a sequence
selected from the group of small non-coding RNAs listed in
Table 4 (see FIG. 4) or is an isoform thereof (having no more
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miR124a
miR195
miR372
miR521
miR568

It was demonstrated in extensive experiments by the inventors that the respective miRNAs are particularly useful markers for vaginal secretions which thus allow the secure identification/determination of an unknown sample as a vaginal
secretion sample. Particularly suitable are the detection of the
following miRNAs as markers for vaginal secretions:
miR124a, miR195, and/or miR372. Particularly suitable is
the use of at least miR124a, miR372, and miR195 as marker
pair respectively marker combination for typing/identifying
vaginal secretion samples.
Additionally or alternatively, at least one small non-coding
RNA is detected which comprises or consists of a sequence
selected from the group of small non-coding RNAs listed in
Table 5 (see FIG. 5) or is an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no more
than 2 base changes) or is derived from the same premiRNA
as the respective small non-coding RNAs listed in Table 5 (see
FIG. 5), as a marker for saliva. The respective miRNAs are
specifically/differentially expressed in saliva samples and are
thus suitable markers for determining/identifying an
unknown sample as a saliva sample. Suitable sequence specific oligonucleotides and probes that are useful for amplifying and/or detecting the corresponding marker miRNAs can
be designed applying known principles e.g. based on the
shown sequence of the miRNA. It is advantageous that at least
two small non-coding RNAs are selected from the following
group of small non-coding RNAs as markers for saliva:
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miR205
miR206
miR208
miR302c
miR509
miR510
miR515-5p
miR518c*
miR525
miR526b
miR551a
miR600
miR606
miR555
miR587
miR658
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It was demonstrated in extensive experiments by the inventors that the respective miRNAs are particularly specific
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markers for saliva which thus allow the secure identification/
determination of an unknown sample as a saliva sample.
Particularly suitable are the detection of the following miRNAs as markers for saliva: miR658, miR606, miR510,
miR526b, miR208 and/ormiR205. Particularly suitable is the
use of at least miR658 and miR205 as marker pair respectively marker combination for typing/identifying saliva
samples. It was demonstrated in extensive experiments by the
inventors that the respective miRNAs are particularly useful
markers for saliva which thus allows the secure identification/
determination of an unknown sample as a saliva sample.
The success and accuracy of any biological assay involving
the use of quantitative expression analysis often also depends
on proper normalization of data. The purpose of normalization is to minimize potential variation that can mask or exaggerate biologically meaningful changes. Quantitative assessments of total RNA in a sample can be affected by various
factors including extraction efficiencies of RNA from different body fluids and substrates upon which they were deposited as well as potential RNA degradation. The currently
available RNA quantification methods are usually not
human-specific and therefore RNA quantity estimations can
also be affected by the presence of contaminating non-human
species. Potential normalization strategies for use in miRNA
expression analysis include the use of housekeeping genes
(mRNA), small RNAs such as 5S rRNA or U6b (a small
nucleolar RNA), and universally expressedmiRNAs. Ideally,
a normalizer should be present in relatively high and consistent abundance in all tissues or cell types, should be of similar
size and found in similar cellular environments as the target
molecule, and be compatible with the analysis methods utilized for the target molecule. Messenger RNAs from housekeeping genes may not be the most suitable targets for normalization of miRNA expression data due to abundance,
degradation rates and amplimer size differences. For
example, universally (and approximately) equally expressed
'housekeeping' miRNAs could be used as normalizers.
Thus, according to one embodiment, the expression of the
marker small non-coding RNA is normalized relative to a
generically expressed small non-coding RNA which can be of
the same or a different type than the marker sample. This
allows a relative quantification of the marker small non-coding RNA and hence ensures a reliable detection independent
of extraction efficiency and sample preservation. The normalization marker may serve as a positive control at the same
time. According to one embodiment, the expression of a small
non-coding RNA is determined for normalisation which is
different from the marker small non-coding RNA to be
detected. To detect a small non-coding RNA for normalisation is advantageous as they would depict the same degradation profile/advantages as the small non-coding RNA
detected as a marker for a particular sample type. The small
non-coding RNA used for normalization has a Ct value close
to the marker small non-coding RNA in order to simplify the
comparison.
According to one embodiment, the small non-coding RNA
used for normalization is selected from the group consisting
ofU6B, U44, Sl 5 or miRNAs which have a similar Ct value
in the samples of interest. The respective small non-coding
RNAs showed good characteristics in the performed tests.
Other examples include U26, U27, U28, U29, U30, U31,
U38B, U43, U48 and U90. The choice of the normaliser may
also be adapted to the sample type or assay as it may provide
further sample specificity (see below). Also more than one
normaliser may be used.
Different normalisation concepts can be used according to
the present invention.

For absolute quantification, e.g. a synthetic miRNA can be
used that can be mixed for more reliable handling or mimic of
background nucleic acid with carrier RNA such as corn or
bacterial RNA. E.g. 50 ng per RT reaction (2.5 ng/µl) of the
carrier can be used. A respective approach enables maximum
quantification of all steps including the reverse transcriptase
step (see below) with minimum effort.
Another normalisation approach which can be used to
quantify the marker small non-coding RNAs and in particular
the miRNAs is the delta delta Ct method. For relative delta
delta Ct quantification, assays for snoRNAs can be used. A
snoRNA with a Ct value close to the marker small non-coding
RNA of interest is an appropriate one as control. Alternatively, if individual expression levels are not determined, e.g.
the snoRNAs U6B and U44 can be used as a general control
for all small non-coding RNAs and in particular miRNAs.
Small nucleolar RNAs ( snoRNAs) participate in the processing and modification of other ribonucleic acids-in particular
rRNA. snoRNAs do not encoded proteins but operate as
"guide" RNAs, by directing catalytically active proteins to
the right places/positions of the RNA. Usually, snoRNAs are
in the cell associated with other proteins and form a so-called
snoRNPs (small nucleolar ribonucleoprotein particle). The
modifications that are introduced by the snoRNPs into the
rRNAs are inter alia essential for the functions of the ribosome.
According to one embodiment, total RNA extracts are first
quantitated e.g. using a RiboGreen fluorescence assay and
equal amounts of total RNA are used in subsequent reverse
transcription assays. However, this normalization strategy
may not be sufficiently precise enough on its own for certain
applications of the present technology due the potential presence of differing levels of non-human sources of RNA in
some forensic samples (e.g. bacteria in saliva and vaginal
secretions). Therefore, one may also employ alternatively or
additionally a delta Ct (deltaCt) metric which measures the
relative abundance of a particular miRNA in relation to e.g. a
small nucleolar RNA, e.g. U6b or U44. U6b is advantageous
due to its high abundance and apparent stability in different
body fluid stains of forensic interest. For example, for high
abundance miRNA candidates whose expression was greater
than e.g. U6b, the deltaCt metric was obtained by subtracting
the Ct value of miRNA from the Ct value of the U6b, whereas
for miRNAs present in lower abundance than U6b, the
deltaCt was obtained by subtracting the Ct value of e.g. U6b
from the Ct value of the miRNA.
According to one embodiment, the method comprises at
least one of the following steps:
a. isolating RNA from the sample
b. optionally quantifying the isolated RNA
c. reverse transcribing the isolated RNA
d. detecting, preferably amplifying, at least one marker
small non-coding RNA.
The respective process steps are routine steps for the person of skill in the art and thus can be easily and routinely
performed. Amplification is preferably performed by PCR in
order to be able to detect the presence or absence of the
marker small non-coding RNAs even in very small samples.
Suitable amplification and detection methods are described
above. The detection is preferably quantitative.
Isolation of the RNA is performed by using conventional
methods. Preferably methods are used which allow the efficient isolation of small RNAs of e.g. less than 1000 or even
500 or 100 nucleotides from a sample. One suitable method is
the standard guanidine isothiocyanate-phenol: chloroform
based extraction method (see e.g. Chomczynski P, Sacchi N
(1987) Single-step method of RNA isolation by acid guani-
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dinium thiocyanate-phenol-chloroform extraction. Anal Biomine the species of origin. The presence of human (or higher
chem 162: 156-159). Numerous non-organic, silica-based
primate) blood would be indicated by the presence of the
unknown sample within the cluster of human blood samples.
extraction kits are now commercially available for the recovIt was shown by experiments, that the U44-normalized assay
ery of miRNAs and, in contrast to the phenol-chloroforms
methods, are easily transferable to an automated platform.
can be used to identify the presence of human or higher
Thus these kits may prove more suitable for use in forensic
primate blood if a positive result for an unknown sample was
casework. An appropriate amount of total RNA (e.g. -1-5 ng)
obtained using the U6b-normalized blood assay. Thus, the
choice of the right normalizer may provide species specificwould be used for reverse transcription (RT). Several reverse
transcription methods are known in the prior art that can be
ity.
used in conjunction with the present invention. For reverse 10
The method/assay according to the present invention suctranscription, the isolated RNA is preferably tailed (e.g. with
cessfully detected the presence of biological material in aged
a poly A tail) in order to allow the reverse transcription of the
and environmentally compromised samples as well as in
small non-coding RNA by using a universal oligonucleotide/
simulated casework samples that included admixed body
adapter recognising the tail. Amplification is performed using
fluid samples, post coital samples and trace body fluid
appropriate oligonucleotides. E.g. a sequence specific oligo- 15 samples and is thus a valuable tool for identifying unknown
nucleotide for the marker small non-coding RNA of interest
sample types. As is outlined above, the method/assay of the
and a oligonucleotide recognising the tail/adapter incorpopresent application is particularly useful for the determinarated due to the tailing/reverse transcription can be used for
tion/identification of forensic samples, and in particular of
amplification. Suitable commercially available kits for
samples of small quantity. The method/assay can also be used
extraction and reverse transcription are e.g. sold by QIAGEN, 20 in combination with conventional methods for identifying the
nature of a sample, e.g. with methods which detect mRNA
such as e.g. the miScript system. Unlike other commercially
available miRNA systems that employ miRNA-specific
targets as markers in order to identify the nature of a sample
types.
reverse transcription strategies, the miScript system allows
cDNA to be produced from all RNA species within the
Also provided is a method for identifying at least one small
sample, including mRNAs and other small non-coding 25 non-coding RNA as a marker for a particular sample type,
RNAs. This could be advantageous in forensic casework
comprising at least the following steps:
where multiple individual reverse transcription reactions
a. determining the expression of at least one candidate
small non-coding RNA in different sample types;
required to analyze a sufficient amount of miRNAs may not
be possible due to a limited amount of genetic material recovb. selecting at least one small non-coding RNA that is
30
ered from most evidentiary items.
differentially expressed in a particular sample type as
The ability to simultaneously reverse transcribe other RNA
marker small non-coding RNA for said sample type.
species, such as mRNAs, may also be useful if parallel assays
A respective screening/identification method allows the
need to be performed for the detection of tissue specific
identification of further small non-coding RNAs that can be
used as markers for different samples, such as tissue and body
mRNAs or housekeeping genes. Suitable methods are also
described in WO 2008/020008, herein incorporated by refer- 35 fluid samples. The sample can be selected from any human
body fluid and tissue samples including but not limited to
ence. An appropriate volume of the RT product to obtain e.g.
blood, menstrual blood, semen, saliva, vaginal secretions,
50 pg (suitable for the blood, saliva, vaginal secretions and
skin, brain, lung, testis, adipose, thymus, muscle, spleen,
menstrual blood assays) or e.g. 500 pg (suitable forthe semen
placenta, bone marrow, skin, uterus, salivary gland and liver
assay) cDNA would be used in the miRNA quantitative real
time PCR (QT-PCR) assay which, according to one embodi- 40 and other suitable related materials obvious to those skilled in
the art. The method is particularly useful for selecting/idenment, uses the miScript SYBR Green PCR system and a
tifying a marker small non-coding RNA for determining the
miRNA specific oligonucleotide. Suitable sequence specific
oligonucleotides and probes that are useful for amplifying
nature (e.g. origin, tissue type) of a forensic sample. The
and/or detecting the corresponding marker small non-coding
small non-cording RNA that is detected is preferably a mature
RNAs, e.g. miRNAs can be designed applying known prin- 45 miRNA. Suitable candidates are disclosed in FIGS. 1 to 5.
ciples based on the sequence of the marker miRNA to be
It is advantageous regarding specificity and sensitivity that
detected.
the small non-coding RNA selected as marker has at least one
of the following characteristics:
According to the method/assay of the present invention, it
is possible to analyse several marker small non-coding RNAs
a. It is expressed in the particular sample for which the
small non-coding RNA serves as marker;
and if desired, at least one, preferably at least two, normalis- 50
ers (e.g. U6b and U44) from a single RT product. Numerous
b. it shows a discriminating/differential expression pattern
RT reactions are not required for the examination of multiple
in a particular type of sample compared to other sample
marker small non-coding RNAs in the same sample. If a
types;
c. it is specifically expressed in a particular sample type;
real-time PCR is performed, the Ct values for each marker
d. it is expressed in higher abundance in a particular sample
small non-coding RNA may then be evaluated to ensure all 55
obtained values are within acceptable ranges. All acceptable
type; and/or
expression data can then be normalized using e.g. U6b in
e. it is expressed in higher abundance in a particular sample
which the Ct value of the miRNA is subtracted from the Ct
type than the small non-coding RNA used for normalivalue ofU6b. The delta Ct values for the at least two marker
sation and is expressed at lower levels than the small
small non-coding RNAs for each sample/body fluid may then 60
non-coding RNA used for normalisation in other sample
be used to position the unknown sample e.g. two-dimensional
types.
In case a Real time PCR is performed, a suitable marker
scatter plot for each body fluid. The identification of the
presence of the sample/body fluid would be confirmed ifthe
small non-coding RNA can be identified by selecting one
which has a significant lower Ct value in a particular sample
unknown sample was found within the cluster of known body
fluid samples. If a positive result is obtained for e.g. blood, 65 type.
In order to ensure that the identified small non-coding
delta Ct values using U44 for miR451 and miR16 (preferably
used in the assay) may then be calculated and used to deterRNAs are the true source of the obtained expression data,
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reverse transcription negative (RT-) samples, to which no
reverse transcriptase is added, is evaluated. Preferably, no
signal is detected in the RT- samples. If a Ct value is, however, obtained for the RT- samples, for these assays, the Ct
values should be preferably below the RT- average.
According to one embodiment the method comprises
a. Isolating RNA from the sample
b. optionally quantifying the isolated RNA
c. reverse transcribing the isolated RNA
d. detecting, preferably amplifying at least one marker
small non-coding RNA.
Details are described above; we refer to the above disclosure.
Also provided is a kit for determining the nature of a
sample, comprising at least one sequence specific oligonucleotide of at least 80% homology, preferably at least 90%
complementary to the target sequence for detecting the presence or absence of at least one marker small non-coding RNA
in a sequence specific marmer. A respective kit allows the easy
and routine identification of samples and is particularly useful
for forensic applications. The advantages of a respective kit
are outlined in detail above. Preferably, the small non-coding
RNA that is detected is a mature miRNA.
The kit may comprise oligonucleotides for detecting the
presence or absence of at least two marker small-non-coding
RNAs in a sample. As is outlined above, the detection of at
least two marker small non-coding RNAs increases the reliability of the kit.
Preferably, the marker small non-coding RNA detected by
the kit has at least one of the following characteristics:
a. it is expressed in the particular sample for which the
small non-coding RNA serves as marker;
b. it shows a discriminating/differential expression pattern
in a particular type of sample compared to other sample
types;
c. it is specifically expressed in a particular sample type;
d. it is expressed in higher abundance in a particular sample
type; and/or
e. it has a significant lower Ct value in a particular sample
type; and/or
f. it is expressed in higher abundance in a particular sample
type than the small non-coding RNA used for normalisation and is expressed at lower levels than the small
non-coding RNA used for normalisation in other sample
types.
The advantages are outlined in detail above; we refer to our
above disclosure.
The kit may comprise at least one sequence specific oligonucleotide for detecting the presence or absence of at least
one marker small non-coding RNA indicative for a sample
type selected from the group consisting of blood, menstrual
blood, semen, vaginal secret and saliva.
The kit may comprise at least one oligonucleotide specific
for at least one small non-coding RNA selected from the
group of small non-coding RNAs listed in Table 1 (see FIG.
1), an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA as the respective small non-coding RNAs listed in
Table 1 (see FIG. 1). A respective specific oligonucleotide is
preferably at least 80% homologous (identical, respectively
complementary) to the respective marker target sequence to
allow sequence specific detection.
The respective miRNAs are specifically/differentially
expressed in blood samples and in particular peripheral blood
and are thus suitable markers for determining/identifying an
unknown sample as a blood sample. It is advantageous that at

least two small non-coding RNAs are detected which are
selected from the following group of small non-coding RNAs
as markers for blood:
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Let7i
miR15a
miR15b
miR16
miR106a
miR106b
miR126
miR182
miR182*
miR185
miR190
miR195
miR374
miR451
miR545
miR624
miR627
miR154*
miR607

or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA. Preferably Let7i, miR16, miR451 and/or
miR15b, most preferred miR451 and miR16 are detected as
marker miRNAs.
It was demonstrated in extensive experiments by the inventors that the respective miRNAs are particularly specific
markers for blood which thus allow the secure identification/
determination of an unknown sample as a blood sample.

The kit may comprise additionally or alternatively at least
one oligonucleotide specific for at least one small non-coding
RNA selected from the group of small non-coding RNAs
listed in Table2 (see FIG. 2),preferablymiR412andmiR451,
or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA as the respective small non-coding RNAs listed in
Table 2 (see FIG. 2). A respective specific oligonucleotide is
preferably at least 80% homologous (identical, respectively
complementary) to the respective marker target sequence to
allow sequence specific detection. The respective miRNAs
are specifically/differentially expressed in menstrual blood
samples and are thus suitable markers for determining/identifying an unknown sample as a menstrual blood sample. It is
advantageous that at least two small non-coding RNAs are
selected from the following group of small non-coding RNAs
as markers for menstrual blood:
miR23a!b
miR33
miR95
miR106b
miR154
miR218
miR369-5p
miR377
miR412
miR423
miR425-3p
miR451
miR452
miR452*
miR484
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derived from the same premiRNA as the respective small
non-coding RNAs listed in Table 4 (see FIG. 4). Preferably
miR124a, miR372 and miR195 are detected as marker
miRNA. A respective specific oligonucleotide is preferably at
least 80% homologous (identical, respectively complementary) to the respective marker target sequence to allow
sequence specific detection. Suitable examples for sequence
specific oligonucleotides are also indicated in Table 4. The
respective miRNAs are specifically/differentially expressed
in vaginal secretion samples and are thus suitable markers for
determining/identifying an unknown sample as a vaginal
secretion sample. It is advantageous that at least two small
non-coding RNAs are selected from the following group of
small non-coding RNAs as markers for vaginal secretion
samples:

miR494
miR648
miR369-5p
miR507
miR648

or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA. Particularly preferred examples were already
described above. It was demonstrated in extensive experiments by the inventors that the respective miRNAs are particularly specific markers for menstrual blood which thus
allow the secure identification/determination of an unknown
sample as a menstrual blood sample even compared to a
peripheral blood sample.
The kit may comprise additionally or alternatively at least
one oligonucleotide specific for at least one small non-coding
RNA selected from the group of small non-coding RNAs
shown in Table3 (see FIG. 3) or anisoform thereof(havingno
more than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or a small non-coding RNA
derived from the same premiRNA as the respective small
non-coding RNAs listed in Table 3 (see FIG. 3), preferably
miR135b and miRl Ob. A respective specific oligonucleotide
is preferably at least 80% homologous (identical, respectively
complementary) to the respective marker target sequence to
allow sequence specific detection. The respective miRNAs
are specifically/differentially expressed in semen samples
and are thus suitable markers for determining/identifying an
unknown sample as a semen sample. It is advantageous that at
least two small non-coding RNAs are selected from the following group of small non-coding RNAs as markers for
semen:
miRlOb
miR99a
miR135a
miR135b
miR204
miR508
miR513
miR517a
miR518f*
miR519d
miR520a*
miR520g/h
miR514
miR518c
miR518e
miR524*
miR611

or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA. It was demonstrated in extensive experiments by
the inventors that the respective miRNAs are particularly
specific markers for semen which thus allow the secure identification/determination of an unknown sample as a semen
sample.
The kit may comprise additionally or alternatively at least
one oligonucleotide specific for at least one small non-coding
RNA selected from the group of small non-coding RNAs
listed in Table 4 (see FIG. 4) or an isoform thereof (having no
more than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or a small non-coding RNA
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miR124a
miR195
miR372
miR521
miR568

or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA. It was demonstrated in extensive experiments by
the inventors that the respective miRNAs are particularly
specific markers for vaginal secretions which thus allow the
secure identification/determination of an unknown sample as
a vaginal secretion sample.
The kit may comprise additionally or alternatively at least
one oligonucleotide specific for at least one small non-coding
RNA selected from the group of small non-coding RNAs
listed in Table 5 (see FIG. 5), preferably miR658 and miR205
or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
and/or a small non-coding RNA derived from the same
premiRNA as the respective small non-coding RNAs listed in
Table 5 (see FIG. 5). A respective specific oligonucleotide is
preferably at least 80% homologous (identical, respectively
complementary) to the respective marker target sequence.
Suitable examples for sequence specific oligonucleotides are
also indicated in Table 5. The respective miRNAs are specifically/differentially expressed in saliva samples and are thus
suitable markers for determining/identifying an unknown
sample as a saliva sample. It is advantageous that at least two
small non-coding RNAs are selected from the following
group of small non-coding RNAs as markers for saliva:
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miR205
miR206
miR208
miR302c
miR509
miR510
miR515-5p
miR518c*
miR525
miR526b
miR551a
miR600
miR606
miR555
miR587
miR658

65

or an isoform thereof (having no more than 5, preferably no
more than 3 or more preferred no more than 2 base changes)
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and/or a small non-coding RNA derived from the same
premiRNA. It was demonstrated in extensive experiments by
the inventors that the respective miRNAs are particularly
specific markers for saliva which thus allow the secure identification/determination of an unknown sample as a saliva
sample.
Preferably, the kit comprises oligonucleotides for at least
two different marker small non-coding RNAs per particular
sample type.
Furthermore, the kit may comprise at least one sequence
specific oligonucleotide for detecting a small non-coding
RNA for normalization. Preferably, the small non-coding
RNA detected for normalization has a Ct value close to the Ct
value of the marker small non-coding RNA. The kit may
comprise at least one sequence specific oligonucleotide for
detecting a small non-coding RNA selected from the group
consisting ofU 6B, U 44, S 15 or miRNAs which have a similar
Ct value in all sample types of interest. Details are outlined
above, we refer to our above disclosure.
The kit may additionally comprise at least one of the following components
a. buffers and/or reagents for isolating RNA from a sample
b. buffers and/or reagents for reverse transcribing RNA
c. buffers and/or reagents for amplification and/or detecti on.
Details regarding the isolation, amplification and detection
were outlined above; we refer to the respective disclosure.
The kit may also comprise a universal oligonucleotide that
can be used in combination with the sequence specific oligonucleotide for amplifying the small non-coding RNAs.
A respective kit is particularly useful in for identifying the
nature and in particular the origin and type of forensic
samples as it provides a reliable tool for determining the
nature of even small samples, in particular forensic samples.
Also provided is an oligonucleotide set for determining the
nature of a sample, said set comprising oligonucleotides for
detecting at least two different small non-coding RNAs per
sample type, wherein said oligonucleotide set has at least one
of the following characteristics:
a. It comprises oligonucleotides hybridising to at least two
small non-coding RNAs comprising or consisting of a
sequence selected from the group of
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b. and/or it comprises oligonucleotides hybridising to at
least two small non-coding RNAs comprising or consisting of a sequence selected from the group of
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miR15a
Let7i
miR15b
miR16
miR106a
miR106b
miR126
miR182
miR182*
miR185
miR190
miR195
miR374
miR451
miR545
miR624
miR627
miR154*
miR607

or hybridising to an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or miRNA derived from
the same premiRNA as the respective miRNAs, preferably miR451 and miR16, as markers for blood;
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miR23a!b
miR33
miR95
miR154
miR218
miR377
miR412
miR423
miR4253p
miR451
miR452
miR452*
miR484
miR494
miR648
miR3695p
miR507
miR648

or hybridising to an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or miRNA derived from
the same premiRNA as the respective miRNAs, preferably miR412 and miR451, as markers for menstrual
blood;
c. and/or it comprises oligonucleotides hybridising to at
least two small non-coding RNAs comprising or consisting of a sequence selected from the group of
miRlOb
miR99a
miR135a
miR135b
miR204
miR508
miR513
miR517a
miR518f*
miR519d
miR520a*
miR520g/h
miR514
miR518c
miR518e
miR524*
miR611

or hybridising to an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or miRNA derived from
the same premiRNA as the respective miRNAs, preferably miRl 35b and miRl Ob, as markers for semen;
d. and/or at it comprises oligonucleotides hybridising to at
least two small non-coding RNAs comprising or consisting of a sequence selected from the group of

miR124a
miR195
miR372
miR521
miR568

or hybridising to an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or miRNA derived from
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the same premiRNA as the respective miRNAs, preferably miR124a, miR372 and miR195, as markers for
vaginal secretions;
e. and/or it comprises oligonucleotides hybridising to at
least two small non-coding RNAs comprising or consisting of a sequence selected from the group of
miR205
miR206
miR208
miR302c
miR509
miR510
miR5155p
miR518c*
miR525
miR526b
miR551a
miR600
miR606
miR555
miR587
miR658

or hybridising to an isoform thereof (having no more
than 5, preferably no more than 3 or more preferred no
more than 2 base changes) and/or miRNA derived from
the same premiRNA as the respective miRNAs, preferably miR658 and miR205, as markers for saliva.
A respective oligonucleotide set is particularly useful for
identifying/typing samples, in particular body fluids. The
features of the respective small non-coding RNAs are
described in detail above. Each oligonucleotide hybridises to
its specific/corresponding marker small non coding RNA.
Hence, ifthe set comprises oligonucleotides hybridising to at
least two small non-coding RNAs, at least two different oligonucleotides are provided wherein each oligonucleotide
recognises a specific marker small non coding RNA. The
oligonucleotides do not need to recognise both sequences
even though this option is included. Some small non coding
RNAs exist with minor sequence variations (e.g. miRNA
isoforms having less than 5, preferably 2 or 3 base changes or
less). They are also encompassed as the individual oligonucleotides can be designed that they also recognize and
hybridise to respective miRNA isoforms or miRNAs which
are derived from the same premiRNA.
FIG. 1-5 show tables 1-5 which depict suitable miRNAs
which are useful markers for different samples, namely blood
(FIG. 1/Table 1), menstrual blood (FIG. 2/Table 2), semen
(FIG. 3/Table 3), vaginal secretions (FIG. 4/Table 4) and
saliva (FIG. 5/Table 5).
As is also shown in FIG. 9, a mature miRNA is made from
a stem loop precursor, typically from one leg of the stem.
When the other leg is detected as a minor component in the
cells, it gets the asterisk. When both strands are detected as
relatively equal contributors, they get 3p and 5p suffix (depending on whether they are closer to the 5' or 3' end of the
premiRNA). Some miRNA have an identical mature
sequence but different names. This naming schema corresponds to the one of miRBase. If several isoforms of a miRNA
exist that can be detected, respective isoforms (having suffices a, b, c etc). Isoforms differ in only a few bases, usually
less than 3. Further isoforms may exist, which are not listed
but could also be detected according to the teachings of the
present invention. "hsa" is the designation for human miRNA
sequence. Particularly preferred variants/isoforms are indicated in the tables.
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FIG. 6 shows, as an example, the results of a miRNA
candidate screening using pooled body fluid samples. The
graph shows absolute Ct values for 25 miRNAs for the pooled
body fluid samples for identification of possible miRNA
marker candidates for the individual body fluids, namely
blood, semen, saliva, vaginal secretions and menstrual blood.
Each body fluid is represented by a symbol (blood--diamond; semen-small square; saliva-triangle; vaginal secretions-large square; menstrual blood-circle).
As can be seen, only few miRNAs depict an expression
profile which makes them suitable as marker small non-coding RNAs according to the present invention. For example,
the graph shows that the miRNAs miR15a, miR15b and
miRl 6 are suitable candidates for blood samples as they show
a desirable discrimination profile compared to the other body
fluids analysed. They can thus be used as a marker for blood.
FIG. 7A to E shows the development of2-D miRNA body
fluid identification assays. Different samples from different
donors were used. Body fluid data clustering using 2-D scatter plots constructed with U6b normalised expression data for
two miRNAs that were particularly advantageous markers for
the respective fluid is shown. The blood assay (FIG. 7A)
shows in the X-axis the llCt miR16 (U6b-miR16), the Y-axis
the fl Ct miR451 (U6b-miR451 ). The semen assay (FIG. 7B)
shows on the X-axis thellCtofmiR135b (U6b-miR135b ), the
Y-axis shows the llCt ofmiRlOb (U6b-miR10b). The saliva
assay (FIG. 7C) shows on the X-axis the llCt of miR205
(U6b-miR205) and on the Y-axis the fl-Ct ofmiR658 (U6bmiR658). The vaginal secretion assay (FIG. 7D) shows on the
X-axis the fl Ct of miRl 24a (U6b-miR124a) and on the Y-axis
the llCT of miR372 (U6b-miR372). The menstrual blood
assay (FIG. 7E) shows on the X-axis llCt miR451 (U6bmiR451), the Y-axis shows the llCt miR412 (U6b-miR412).
The body fluids are presented by symbols. The blood is
represented by squares, the semen by diamonds, saliva by
triangles, vaginal secretions by a circle and menstrual blood
by open squares. The body fluid of interest on each assay is
circled and labelled.
A pair of markers was used, as the use of two markers
provides more security for identifying/typing a specific
sample. As can be seen, the tested markers are plotted in the
shown 2-D assay in the same quadrant which indicates that
they are equally suitable. Furthermore, as can be seen from
the results obtained from the different samples, the tested
markers are also highly specific for their respective sample
type.
FIG. 8 demonstrates the stability of miRNA expression
even in environmentally compromised blood samples.
FIG. 9 illustrates the generation of mature miRNAs
according to one assumed embodiment (figure obtained from
public sources). The genes encoding miRNAs are much
longer than the processed mature miRNA molecule. miRNAs
are first transcribed as primary transcripts or pri-miRNA with
a cap and poly-A tail and processed to short, approximately
70-nucleotide stem-loop structures known as pre-miRNA in
the cell nucleus. This processing is performed in animals by a
protein complex known as the Microprocessor complex, consisting of the nuclease Drosha and the double-stranded RNA
binding protein Pasha. These pre-miRNAs are then processed
to mature miRNAs in the cytoplasm by interaction with the
endonuclease Dicer, which also initiates the formation of the
RNA-induced silencing complex (RISC). This complex is
responsible for the gene silencing observed due to miRNA
expression and RNA interference. The pathway is also different for miRNAs derived from intronic stem-loops; these are
processed by Dicer but not by Drosha. Either the sense strand
or antisense strand of DNA can function as templates to give
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rise to miRNA. Most pre-miRNAs don't have a perfect
double-stranded RNA (dsRNA) structure topped by a terminal loop. There are few possible explanations for such selectivity. One could be that dsRNAs longer than 21 base pairs
activate interferon response and anti-viral machinery in the
cell. Another plausible explanation could be that the thermodynamic profile of pre-miRNA determines which strand will
be incorporated into Dicer complex. Indeed, clear similarities
between pri-miRNAs encoded in respective ( 5'- or 3 '-) strands
have been demonstrated. When Dicer cleaves the pre-miRNA
stem-loop, two complementary short RNA molecules are
formed, but only one is integrated into the RISC complex.
This strand is known as the guide strand and is selected by the
argonaute protein, the catalytically active RNase in the RISC
complex, on the basis of the stability of the 5' end. The
remaining strand, known as the anti-guide or passenger
strand, is degraded as a RISC complex substrate. After integration into the active RISC complex, miRNAs base pair with
their complementary mRNA molecules and induce mRNA
degradation by argonaute proteins, the catalytically active
members of the RISC complex.

months sample is represented by an open diamond. As can be
seen, the results are basically identical for all samples despite
the fact that the additionally tested blood samples were aged/
heat treated. The results demonstrate, that for example, blood
stains kept at room temperature for even two years and even at
elevated temperatures still cluster as blood stains and can thus
be securely identified by detecting the marker miRNAs. This
proves that the present detection method is highly reliable
also for difficult and/or compromised samples, which are
often encountered in forensic samples. The marker miRNA
are stable in the sample and thus provide a reliable markerthat
can be detected to identify/type samples. Additional test were
performed.
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EXAMPLES
For identifying useful marker small non-coding RNAs and
in particular miRNAs, the commercially available "Human
miScript Oligonucleotide Assay Set Vl .0-miRNA-specific
oligonucleotides for 452 human miRNAs"; QIAGEN cat no
218411 can be used to screen for markers useful in forensic
testing. Suitable candidates are listed in FIG. 1 to 5.
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Example 1
Tissue Identification
35

4 different sample types are collected from 5 different
individuals of different sex (if applicable) and age: semen,
blood, saliva, vaginal secretion. RNA is extracted from these
samples and RNA pools are generated from RNA from all 5
donors. RNA is quantified and subjected to real time PCR
based analysis to determine expression levels for the individual miRNAs respectively. Candidate miRNAs are identified that show significantly heightened or lowered expression
levels for certain samples, e.g. body fluids.
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Example 2
Stability
Different sample types (semen, blood, saliva, vaginal
secretion) are collected, stored at room temperature and total
RNA is extracted at different time points from 0 to 18 months.
miRNAs are found to be highly stable.
The ability to detect the body fluids in environmentally
compromised biological stains was evaluated by the analysis
of samples stored at room temperature (one year and two
years) and at 37° for six months. The blood assay was performed as described above. The markers miRl 6 and MiR451
were used for detection. The X-axis indicates the ti.Ct of
miR16, the Y-axis the ti.Ct ofmiR451.
Several body fluids and the compromised samples were
tested. Blood is indicated by squares, semen by diamonds,
saliva by triangles and vaginal secretions by circles. The
known blood samples (see above) are circled in the graph. The
room temperature one year sample is represented by an open
triangle in the blood section, the room temperature two year
sample is represented by an open square and the 37° six
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To further substantiate the respective results, additional
experiments were performed.
3.1. Methods
a.) Preparation of Body Fluid Stains
Body fluids were collected from volunteers using procedures approved by the University of Central Florida's Institutional Review Board. Informed written consent was
obtained from each donor. Blood samples were collected by
venipuncture into additive-free vacutainers and 50 µl aliquots
were placed onto cotton cloth and dried at room temperature.
Freshly ejaculated semen was provided in sealed plastic tubes
and stored frozen until they were dried onto sterile cotton
swabs. Saliva samples were provided in sealed plastic tubes
and stored frozen until they were dried onto sterile cotton
swabs. Buccal samples were collected from donors using
sterile swabs by swabbing the inside of the donor's mouth.
Semen-free vaginal secretions and menstrual blood were collected using sterile cotton swabs. All samples were stored at
-20° C. until needed. A 50 µl stain or a single cotton swab was
used for RNA isolation.
Total RNA from 20 human tissues (adipose, bladder, brain,
cervix, colon, esophagus, heart, kidney, liver, lung, ovary,
placenta, prostate, skeletal muscle, small intestine, spleen,
testes, thymus, thyroid, and trachea) included in the
FirstChoice® Human Total RNA Survey Panel was obtained
from Applied Biosystems/Ambion (Austin, Tex.). All tissues
included in the panel were 3-donor pooled samples and were
certified to contain small RNAs including miRNAs and snRNAs. Total RNA from human skin was obtained from Biochain Institute, Inc (Hayward, Calif.).
Blood samples from 12 non-primate animal species (dog,
cat, horse, crane, cow, sheep, coyote, tortoise, lamb, Patagonian cavy, ferret, deer) and 10 primate species (spider monkey, rhesus macaque, pig-tailed macaque, brown lemur,
chimpanzee, baboon, howler monkey, cynomolgous monkey,
African green monkey, and spot-nosed guenon) were
obtained from various sources: Tuscawilla Oaks Animal Hospital, Oviedo, Fla. (dog, cat); HemoStat Laboratories, Dixen,
Calif. (sheep, cow, horse); Central Florida Zoo, Sanford, Fla.
(brown lemur, howler monkey, spot-nosed guenon); Brevard
Zoo, Melbourne, Fla. (crane, coyote, tortoise, lamb, Patagonian cavy, spider monkey, rhesus macaque, pig-tailed
macaque); donation from laboratory members (coyote, deer);
West End Animal Hospital, Gainesville, Fla. (ferret). Liquid
blood samples from African green monkey, cynomolgus
monkey, baboon and chimpanzee were obtained from Bioreclamation, Inc. (Westbury, N.Y.). For all blood samples, fifty
microliter aliquots were placed on cotton cloth and dried
overnight at room temperature.
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Saliva samples from two cats and two dogs were collected
by swabbing the inside of the animal's mouth using sterile
cotton swabs. A primate saliva sample (spot-nosed guenon)
was obtained by donation from the Central Florida Zoo (Sanford, Fla.).
b) RNA Isolation
Total RNA was extracted from blood, semen, saliva, vaginal secretions and menstrual blood with guanidine isothiocyanate-phenol:chloroform and precipitated with isopropanol
[58]. Briefly, 500 DI of pre-heated (56° C. for 10 minutes)
denaturing solution (4M guanidine isothiocyanate, 0.02M
sodium citrate, 0.5% sarkosyl, O.lM beta-mercaptoethanol)
was added to a 1.5 mL Safe Lock tube extraction tube (Eppendorf, Westbury, N.Y.) containing the stain or swab. The
samples were incubated at 56° C. for 30 minutes. The swab or
stain pieces were then placed into a DNA IQ™ spin basket
(Promega, Madison, Wis.), re-inserted back into the original
extraction tube, and centrifuged at 14,000 rpm (16,000xg) for
5 minutes. After centrifugation, the basket with swab/stain
pieces was discarded. To each extract the following was
added: 50 µI 2 M sodium acetate and 600 µI acid phenol:
chloroform (5: 1), pH 4.5 (Applied Biosystems/Ambion). The
samples were placed at 4 ° C. for 30 minutes to separate the
layers and then centrifuged for 20 minutes at 14,000 rpm
(16,000xg). The RNA-containing top aqueous layer was
transferred to a new 1.5 ml microcentrifuge tube, to which 2
µI of GlycoB!ue™ glycogen carrier (Applied Biosystems/
Ambion) and 500 µI of isopropanol were added. RNA was
precipitated for 1 hour at -20° C. The extracts were then
centrifuged at 14,000 rpm (16,000xg). The supernatant was
removed and the pellet was washed with 900 µI of 75%
ethanol/25% DEPC-treated water. Following a centrifugation
for 10 minutes at 14,000 rpm (16,000xg), the supernatant was
removed and the pellet dried using vacuum centrifugation
(56° C.) for 3 minutes. Twenty microliters of pre-heated (60°
C. for 5 minutes) RNAsecure™ solution (Applied Biosystems/Ambion) was added to each sample followed by an
incubation at 60° C. for 10 minutes. Samples were used
immediately or stored at -20° C. until needed.
c) DNase I Digestion
Six units of TURBO™ DNase I (2U/µl) (Applied Biosystems/Ambion, Inc.) and2.2 µI ofTurbo DNase I Buffer(lOx)
were added to each RNA extract and incubated at 37° C. for
1 hour. The DNase was inactivated at 75° C. for 10 minutes.
The samples were used immediately or stored at -20° C. until
needed. Alternatively, DNase digestion was performed using
the Turbo DNA-free™ kit (Applied Biosystems/Ambion)
according to the manufacturer's protocol.
d) RNA Quantitation
RNA extracts were quantitated with Quant-iT™
RiboGreen® RNA Kit (Invitrogen, Carlsbad, Calif.). Fluorescence was determined using a Synergy™ 2 Multi-Mode
microplate reader (BioTek Instruments, Inc., Winooski, Vt.).
e) cDNA Synthesis
For the reverse transcriptase (RT) reaction, the miScript
Reverse Transcription Kit (Qiagen, Valencia, Calif.) was used
according to manufacturer's protocols. One nanogram of
total RNA from blood, semen, vaginal secretions and menstrual blood extracts and 5 ng of total RNA from semen
extracts were used in the RT reactions. A reverse transcription
negative reaction (containing total RNA and reaction buffer
but no reverse transcriptase enzyme mix) was performed for
each sample.
f) Real-Time Polymerase Chain Reaction
Real-time PCR was performed using the Relative Quantitation protocol on an ABI Prism 7000 Sequence Detection
System (Applied Biosystems). One microliter of the 1 ng

RT-reaction (blood, saliva, vaginal secretions, menstrual
blood) and two microliters of the 5 ng RT-reaction (semen)
were amplified using the miScript SYBR® Green PCR kit
and a 1Ox miScript primer assay (Human mi Script Primer
Assay Set vl.O, Qiagen) according to manufacturer's protocols, with minor modifications. A reduced reaction volume of
25 µI was used as well as an increased number of amplification cycles (from 35-40 to 50 cycles). Additional snRNA
(U6b)andsnoRNA(U26, U27, U28, U29, U30, U31, U38B,
U43, U44, U48 and U90) primer assays for normalization
studies were obtained from Qiagen.
g) Menstruation Cycle Samples
Two female individuals donated vaginal swabs over the
course of a 28-day period. Females at two different life stages
participated in the study, one experiencing menstruation at
regular intervals and one in perimenopause. Participants were
asked to collect a single semen-free vaginal swab during each
day of the study, with the first day of collection starting on the
first day of menstruation if applicable.
h) Multiple-Source Samples
Pooled Samples
Five-donor pooled samples were used for the initial
miRNA screening in forensically relevant fluids. Total RNA
from each individual sample was extracted and quantitated as
described above. Equal quantities of total RNA from each
donor were combined in order to produce a 1 ng/01 pooled
sample for blood, saliva, vaginal secretions and menstrual
blood, and a 5 ng/µl pooled sample for semen. A 1 µI aliquot
of each pooled sample was used in the reverse transcription
assay.
Two Fluid Mixtures
Admixed body fluid samples (blood-semen, blood-saliva,
blood-vaginal secretions, semen-saliva, semen-vaginal secretions and saliva-vaginal secretions) were created by combining two different body fluid stains or swabs (50 µI stain for
blood, semen and saliva, or a single vaginal secretion swab) in
the same tube. Total RNA was extracted as described above.
i) Mock Casework Samples
Saliva Samples
Swabs of a beverage container lid (plastic coffee cup lid,
water bottle) using a sterile cotton swab were collected after
being deposited by volunteers. Saliva from a male donor was
deposited onto the skin of a female donor. Afterthe saliva was
allowed to dry, the skin was swabbed using a sterile cotton
swab. Portions of the outer wrapping of used cigarette butts
(collected from a male and female donor) were removed for
extraction. Total RNA was extracted as described above.
3.2. Results
3.2.1. miRNA BodyF!uID Specificity
a) Body Fluid/Tissue Specificity
The initial studies were performed using five samples per
body fluid ( se above). In order to ensure the specificity of each
assay, additional body fluid samples were tested (n= 10-20 for
the body fluid of interest, n=8- l 0 for the other body fluids not
being assayed for).
Blood
Nineteen human blood samples (including the five previously tested samples) were analyzed using the blood miRNA
assay (miR16/deltaCt miR451). The blood sample donors,
both male and female, ranged in age from 15 months to 84
years old. As before, all of the human blood samples were
found in a distinct cluster in the upper right quadrant separated from all other body fluids. All vaginal secretion samples
were found in the lower left quadrant and there was considerable overlap of the semen and saliva samples, which were
spread out over the two lower quadrants and the upper right
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quadrant. The buccal samples were located closer to the blood
samples than any of the other fluids but were still well separated from each other.
Semen
Eleven human semen samples (five previously tested
samples included) were tested using the semen miRNA assay
(deltaCt miR135b and deltaCt miRlOb). Samples were
obtained from adult males ranging in age from 26-52 years
old. All of the semen samples are found in a distinct cluster
separated from all other body fluids. Samples from two vasectomized males were included in the study in order to determine ifthe semen assay was specific to sperm cells. Both of
the samples from the vasectomized males were detected
amongst the semen samples from non-vasectomized males,
thereby demonstrating the ability of the assay to accommodate non-sperm containing semen samples. The detection of
semen from both vasectomized and non-vasectomized males
could indicate that the two semen miRNA candidates are
present in seminal fluid or in epithelial cells from the male
reproductive tract. Overall, fewer miRNAs were detected in
semen compared to the other biological fluids and those that
were present were often found in much lower abundance. The
low abundance of these miRNAs may be explained if detection is obtained from the low level of non-sperm cells present
in semen. The cellular and non-cellular components of semen
could be separated and examined for the presence of both of
the semen miRNA candidates to determine if the miRNAs
used in the semen assay are cellular based.
Saliva
Eighteen human saliva samples (including the five previously tested samples) were tested using the saliva miRNA
assay (miR205/miR658). Samples were obtained from both
male and female donors ranging in age from 26-58 years old,
and included both liquid whole saliva samples (n=9) and
buccal swabs (n=9). All of the liquid saliva and buccal scrapings samples were located together in a distinct cluster separate from the other body fluids tested. They were clustered in
the upper right quadrant with the exception of one buccal
sample which, although part of the cluster, was slightly outside the quadrant. The vaginal secretions, blood and semen
samples were mainly located in the lower left quadrant with a
few samples just inside the lower right quadrant. The ability
to identify both liquid saliva and buccal samples is an important finding since both whole saliva and buccal cells are
encountered in forensic specimens.
Vaginal Secretions
Eleven vaginal secretion samples (including the five previously analyzed samples) were collected from adult females
ranging in age from 28-65 years old and tested using the
vaginal secretions miRNA assay (miR124a/deltaCt miR372).
All vaginal secretion samples, except for one 'false negative',
were located together in a distinct cluster in the lower right
quadrant separate from the other body fluids. Since the whole
saliva sample set was the closest to the vaginal cluster, additional saliva samples comprising five buccal epithelial
samples were tested using the vaginal secretions assay in
order to determine whether the vaginal epithelial and oral
epithelial cells were distinguishable. While the buccal epithelial cells clustered closer to the vaginal secretion data points
than the whole saliva samples, there was still a clear separation between the two body fluids.
Other Human Tissues
Despite reports in the current literature of the identification
of tissue-specific miRNAs, it has been suggested that a majority of miRNAs will be expressed in the majority of tissues.
While all of the miRNAs included in the body fluid identification panel described above were detected in each body

fluid, their differential expression enabled each of the four
body fluids to be distinguished.
Total RNA from twenty-one human tissues including adipose, brain, cervix, heart, liver, lung, placenta, prostate, skeletal muscle, testes, thyroid, trachea, bladder, spleen, thymus,
ovary, kidney, colon, esophagus, small intestine
(FirstChoice® Human Total RNA Survey Panel, Applied
Biosystems/Ambion) and skin (Biochain Institute, Inc.), was
analyzed using the miRNA panel. Each total RNA sample
included in the FirstChoice® panel comprised RNA from at
least three different donors and was certified to contain small
RNAs (miRNA, siRNA and snRNA). As expected, the miRNAs included in the panel were detected in each of the tissue
samples but again in varying abundance. The high degree of
specificity of each of the miRNA body fluid identification
assays was confirmed since all of the tissue samples exhibited
expression profiles that differed from that of the appropriate
body fluid in each of the four assays discussed above.
For the blood assay, both miR16 and miR451 were
detected in all twenty-one tissues with the exception of the
small intestine where miR451 was not detected. MiR451 was
found in the highest abundance in lung and placenta whereas
miRl 6 was found in the highest abundance in lung and prostate. However, despite their higher abundance in these tissues
compared to the rest of the samples, their abundance was still
lower than that in human blood samples. When the tissue
samples were evaluated using blood assay and the data analyzed using the 2D scatter plot, all of the tissue samples were
present in the lower left quadrant of the scatter plot whereas
the blood samples were tightly clustered in the upper right
quadrant.
Both the semen markers, miRl 35b and miRl Ob, were also
detected in all of the twenty-one tissues with many present in
moderate to high abundance. MiR135b was detected in highest abundance in testes and thyroid, whereas miRl Ob was
detected in high abundance in numerous tissues including
testes, adipose, cervix, ovary, kidney and colon. As a result of
the high abundance of these miRNAs in numerous tissues, the
separation between the human semen sample cluster and the
tissue samples was not as great in the 2D scatter plot as that
observed for the blood assay.
One of the saliva miRNA markers, miR658, was present in
low abundance in all of the tissue samples. MiR205 was
present in moderate abundance in the cervix, placenta and
prostate tissue but in low abundance in all other tissues. The
2D plot showed the tissue samples located in the lower left
quadrant with a significant separation from the saliva
samples, which were located in the upper right quadrant.
For the vaginal secretions assay all tissue samples were
located in the lower left quadrant separated from the vaginal
secretions samples that were located in the lower right quadrant. Several published studies have identified miR124a as a
brain-specific miRNA. While miR124a was found in highest
abundance in brain compared to the other tissues examined,
the expression level observed in brain was still lower than that
we observed for vaginal secretions. Due to these differences
in expression, the brain sample was located closer to the
vaginal secretions samples on the two-dimensional plot but
was still present in the lower left quadrant. The Ct values for
miR372 rangedfrom32 to >40 for all tissue samples, with the
lowest Ct value obtained from placenta.
Species Specificity
Optimal forensic analysis not only requires an assay to
possess tissue specificity but it also should exhibit restricted
species specificity. To check this, a number of non-human
blood samples were analyzed including twelve animal species (dog, cat, horse, crane, cow, coyote, sheep, tortoise, lamb,
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Patagonian cavy, ferret, deer) and ten non-human primate
species (spider monkey, rhesus macaque, pig-tailed macaque,
brown lemur, chimpanzee, baboon, howler monkey, cynomolgus monkey, African green monkey, spot-nosed guenon).
A smaller number of non-human saliva samples were available tested and included cat, dog and one primate (spot-nosed
guenon). Semen and vaginal secretion samples from nonhuman species were not available for testing, but such body
fluids from non-human species are rarely encountered in
casework.
For all of the non-human species blood samples, miR451,
miR16, and U6b were detected in significant abundance. All
of the non-human samples were found in close proximity to
the human blood data points. Two animals (ferret and coyote)
and four primates (chimpanzee, baboon, African green monkey, and cynomolgus monkey) were located directly within
the human blood cluster. While only a small number of the
species tested were clustered within the human blood
samples, the small distance between the human data points
and the remaining animal species would make it difficult to
differentiate human and non-human blood samples with any
degree of confidence using this assay.
Saliva samples from two dogs and two cats were used to
examine the species specificity of the saliva miRNA assay.
Negative results (i.e. not found in the human saliva data
cluster) were obtained for the both of the cat and dog samples.
While an extensive number of animal saliva samples were not
available for testing, cat and dog represent animals that could
be frequently encountered at crime scenes in forensic casework.
As a result of the observed species specificity of the blood
assay, an improvement was developed in order to provide a
more forensically relevant assay. Attempts were made to
identify an alternative small RNA to be used for normalization of the miRNA expression data that would also allow for
a differentiation of human and non-human blood stains. The
expression of 11 small nucleolar RNAs (snoRNAs), including U26, U27, U28, U29, U30, U31, U38B, U43, U44, U48
and U90, was examined in both human and non-human blood
samples in order to determine if a human specific normalizer
could be identified. Several of the snoRNAs, including U26,
U28, U30, U44, and U90, were found in very low abundance
or were not detected in the non-human samples. However, the
abundance of these snoRNAs in the some of the human body
fluids was also quite low. For example, the Ct value for U44,
U26, U28, and U90 in semen was over 40 whereas the Ct for
U30 was acceptable for semen but was close to 40 for blood
and saliva. Therefore, none of the snoRNAs tested were determined to be suitable for use a universal normalizer for all
body fluids.
While an alternative universal normalizer was not identified, several of the snoRNAs, including U26, U28 and U44,
were present in low abundance in non-human blood samples
and in higher abundance in human blood samples. Therefore,
it was possible that one of these snoRNAs could be used to
normalize only the blood assay and provide the desired species specificity. U44 was selected as the top snoRNA candidate due to its high abundance in blood, its low abundance in
the animal blood samples, but also because of its low abundance or absence in most of the primate samples. When the
2D scatter plot was constructed using the U44-normalized
data, the clustering that was achieved with the U6b-normalized assay was not achieved and overlap of the semen, saliva
and blood data was observed. However, it was evident from
the 2D scatter plot that there was a clear separation between
the human blood data points and the non-human blood
samples. Based on these results, it was determined that the

U44-normalized assay could be used to identify the presence
of human or higher primate blood if a positive result for an
unknown sample was obtained using the U6b-normalized
blood assay.
b) Simulated Forensic Casework Samples
The initial studies described above demonstrated the sensitivity (50 pg ofinput cDNA), specificity (no cross-reactivity
with human tissues) and stability (detection in environmentally compromised samples) of the developed miRNA assays
for body fluid identification. However, forensic evidentiary
items may contain only trace amounts of genetic material and
may also include the presence of multiple different biological
fluids. Thus it is important to test the performance of the
miRNA BodyFluID assays according to the present invention
with such samples and we accomplished this by the preparation and analysis of simulated casework samples.
Saliva
Genetic profiles can be routinely recovered from trace
amounts of salivary fluids from items such as used cigarette
butts and beverage containers. Therefore if the presence of
trace amounts of saliva could be detected on these items, it
may provide investigators with an indication of which evidentiary items may be useful for the subsequent recovery of
DNA. Furthermore, saliva recovered from the skin of a victim
could be useful in the investigation of oral assault cases. In
order to determine if the saliva miRNA assay could detect
trace amounts of saliva in such samples, total RNA was recovered from swabs of beverage container lids, human skin on
which saliva had been deposited, and used cigarette butts. All
of the simulated casework samples, except for one of the
swabs taken from a beverage container lid, were located clustered with the known human saliva samples in the upper right
quadrant.
Blood
Total RNA was recovered from the cotton pad of an adhesive bandage used to cover a small cut on the finger of a
female donor. The cotton pad of the bandage contained blood
in the form of a small reddish-brown stain. When the bandage
sample was evaluated with the blood assay, the sample data
was located in the upper right quadrant on the two-dimensional scatter plot clustered with the known blood samples.
The same sample was subsequently evaluated with the U44normalized blood miRNA assay in order to determine ifthe
blood present on the bandage was of human origin. The
location of the sample on the two-dimensional U44-normalized scatter plot was upper right quadrant clustered with the
known human blood samples confirming the presence of
human blood present on the bandage.
Semen and Vaginal Secretions
A significant number of samples processed in an operational forensic DNA laboratory involve the analysis of evidence recovered from sexual assaults. Often only a small
amount of semen from the perpetrator will be present
amongst a vast excess of a female victim's biological material. For an assay to be useful in forensic casework, it must be
able to detect the small amount of semen that may be present
and not be masked by the excess vaginal material present. In
order to determine the potential utility of the semen miRNA
assay forthe analysis of sexual assault evidence, a vaginal and
cervicovaginal swab was collected from a female donor 18
hours post-coitus. The vaginal and cervicovaginal swabs
were collected in order to determine if semen would be
detected in different regions of the vaginal canal. To insure
that residual semen from prior sexual relations were not
present, a pre-coital cervicovaginal swab was also obtained
before coitus commenced but after an abstinence period of
seven days. The presence of semen was detected on both the
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vaginal and cervicovaginal swabs taken 18 hours post-coitus.
The pre-coital swab was negative for the presence of semen.
The presence of vaginal secretions was detected in the vaginal
swab, cervicovaginal swab and the pre-swab using the vaginal secretions assay.
Body Fluid Mixtures
Body fluid mixtures other than the common semen-vaginal
secretions encountered in sexual assault cases may also be
present in forensic evidentiary samples. Thus additional body
fluid mixtures samples, including two blood-semen and one
semen-saliva mixtures were also evaluated. The miRNA
expression profile for each mixture using all four body fluid
assays (blood, semen, saliva, and vaginal secretions) was
determined. Blood and semen were correctly identified in
both of the blood-semen mixture samples. On the blood assay,
the admixed samples were located in the upper right quadrant
clustered with the known blood samples. On the semen assay,
the samples were located in the upper portion of the lower
right quadrant clustered with the known semen samples. The
absence of saliva and vaginal secretions was also demonstrated with the blood-semen mixture samples located in the
lower left quadrants. Semen and saliva were also correctly
identified in the semen-saliva mixture sample with the sample

clustered with the known samples on each plot. The absence
of blood and vaginal secretions was also demonstrated.
The examples demonstrate that miRNAs are present in
total RNA isolates from body fluid stains in sufficient quantity
for analysis. A preferred panel of 9 differentially expressed
miRNAs for the identification of the body fluid origin of
biological stains was tested using suitable oligonucleotides in
detail as described above. The following marker miRNAs are
included in said panel: miR451 and miRl 6 for the identification of blood, miR135b and miRlOb for the identification of
semen, miR658 and miR205 for the identification of saliva,
miRl 24a and miR3 72 for the identification of vaginal secretions, and miR412 which is used in combination with the
blood candidate miR451 for the identification of menstrual
blood. The normalized expression of each of the miRNA pairs
exhibits a body fluid-specific expression pattern which allows
for an identification of the body fluid of interest.
The respective miRNA assays successfully detected the
presence of biological material in aged and environmentally
compromised samples as well as in simulated casework
samples that included admixed body fluid samples, post coital
samples and trace body fluid samples. Additional miRNA
candidates for use in the body fluid identification assays can
be identified using the methods described herein.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

1

ugagguagua gguuguauag uu

<210>
<211>
<212>
<213>

2

ugagguagua gguugugugg uu

3

ugagguagua gguuguaugg uu

22

SEQ ID NO 4
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

4

agagguagua gguugcauag uu

<210>
<211>
<212>
<213>

22

SEQ ID NO 3
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

<210>
<211>
<212>
<213>

22

SEQ ID NO 2
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

<210>
<211>
<212>
<213>

227

SEQ ID NO 5
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

22
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32
-continued

<400>

SEQUENCE, 5

ugagguagga gguuguauag uu

22

<210> SEQ ID NO 6
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE,

ugagguagua gauuguauag uu

22

<210> SEQ ID NO 7
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 7

ugagguagua guuuguacag uu

22

<210> SEQ ID NO 8
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 8

ugagguagua guuugugcug uu

22

<210> SEQ ID NO 9
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 9

uggaagacua gugauuuugu ugu

23

<210> SEQ ID NO 10
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 10

uagcagcaca uaaugguuug ug

22

<210> SEQ ID NO 11
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 11

uagcagcaca ucaugguuua ca

22

<210> SEQ ID NO 12
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 12

uagcagcacg uaaauauugg cg

<210> SEQ ID NO 13
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens

22
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33
-continued
<400>

SEQUENCE, 13

caaagugcuu acagugcagg uag

23

<210> SEQ ID NO 14
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 14

uaaggugcau cuagugcaga uag

23

<210> SEQ ID NO 15
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 15

uaaggugcau cuagugcagu uag

23

<210> SEQ ID NO 16
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 16

acugcccuaa gugcuccuuc ugg

23

<210> SEQ ID NO 17
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 17

ugugcaaauc uaugcaaaac uga

23

<210> SEQ ID NO 18
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 18

uaaagugcuu auagugcagg uag

23

<210> SEQ ID NO 19
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 19

cauugcacuu gucucggucu ga

22

<210> SEQ ID NO 20
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 20

uucaaguaau ucaggauagg u

<210> SEQ ID NO 21
<211> LENGTH, 22
<212> TYPE, RNA

21
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36
-continued

<213> ORGANISM,
<400>

Homo sapiens

SEQUENCE, 21

uguaaacauc cuacacucag cu

22

<210> SEQ ID NO 22
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 22

uguaaacauc cucgacugga ag

22

<210> SEQ ID NO 23
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 23

uguaaacauc cuugacugga ag

22

<210> SEQ ID NO 24
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 24

caaagugcug uucgugcagg uag

23

<210> SEQ ID NO 25
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 25

uuuggcacua gcacauuuuu gcu

23

<210> SEQ ID NO 26
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 26

agcagcauug uacagggcua uga

23

<210> SEQ ID NO 27
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 27

aaaagugcuu acagugcagg uag

23

<210> SEQ ID NO 28
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 28

uaaagugcug acagugcaga u

<210> SEQ ID NO 29
<211> LENGTH, 23

21
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38
-continued

<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 29

agcagcauug uacagggcua uca

23

<210> SEQ ID NO 30
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 30

ucguaccgug aguaauaaug cg

22

<210> SEQ ID NO 31
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 31

cauuauuacu uuugguacgc g

21

<210> SEQ ID NO 32
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 32

ucacagugaa ccggucucuu u

21

<210> SEQ ID NO 33
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 33

cagugcaaug uuaaaagggc au

22

<210> SEQ ID NO 34
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 34

ucagugcacu acagaacuuu gu

22

<210> SEQ ID NO 35
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 35

ucagugcauc acagaacuuu gu

22

<210> SEQ ID NO 36
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 36

aaaguucuga gacacuccga cu

<210> SEQ ID NO 37

22
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39

40
-continued

<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 37

aaguucuguu auacacucag gc

22

<210> SEQ ID NO 38
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 38

ucucccaacc cuuguaccag ug

22

<210> SEQ ID NO 39
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 39

ucgaggagcu cacagucuag u

21

<210> SEQ ID NO 40
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 40

cuagacugaa gcuccuugag g

21

<210> SEQ ID NO 41
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 41

aacauucaac gcugucggug agu

23

<210> SEQ ID NO 42
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 42

aacauucaac cugucgguga gu

22

<210> SEQ ID NO 43
<211> LENGTH, 24
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 43

uuuggcaaug guagaacuca cacu

24

<210> SEQ ID NO 44
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 44

ugguucuaga cuugccaacu a

21
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41

42
-continued

<210> SEQ ID NO 45
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 45

uauggcacug guagaauuca cu

22

<210> SEQ ID NO 46
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 46

uggagagaaa ggcaguuccu ga

22

<210> SEQ ID NO 47
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 47

ugauauguuu gauauauuag gu

22

<210> SEQ ID NO 48
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 48

caacggaauc ccaaaagcag cug

23

<210> SEQ ID NO 49
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 49

uguaacagca acuccaugug ga

22

<210> SEQ ID NO 50
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 50

uagcagcaca gaaauauugg c

21

<210> SEQ ID NO 51
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 51

cugugcgugu gacagcggcu ga

22

<210> SEQ ID NO 52
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 52

augaccuaug aauugacaga c

21
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44
-continued

<210> SEQ ID NO 53
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

53

cagugcaaua guauugucaa age

23

<210> SEQ ID NO 54
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

54

cagugcaaug auauugucaa age

23

<210> SEQ ID NO 55
<211> LENGTH, 20
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

55

acugccccag gugcugcugg

20

<210> SEQ ID NO 56
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

56

gccccugggc cuauccuaga a

21

<210> SEQ ID NO 57
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

57

cuagguaugg ucccagggau cc

22

<210> SEQ ID NO 58
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

58

ucccuguccu ccaggagcuc acg

23

<210> SEQ ID NO 59
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

59

ugagcgccuc gacgacagag ccg

23

<210> SEQ ID NO 60
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

60

uuauaaagca augagacuga uu

22

US 8,936,909 B2

45

46
-continued

<210> SEQ ID NO 61
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

61

cggguggauc acgaugcaau uu

22

<210> SEQ ID NO 62
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

62

uuauaauaca accugauaag ug

22

<210> SEQ ID NO 63
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

63

aaugacacga ucacucccgu uga

23

<210> SEQ ID NO 64
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

64

uccuguacug agcugccccg ag

22

<210> SEQ ID NO 65
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

65

cggggcagcu caguacagga u

21

<210> SEQ ID NO 66
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

66

uaauccuugc uaccugggug aga

23

<210> SEQ ID NO 67
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

67

ucagcaaaca uuuauugugu gc

<210> SEQ ID NO 68
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

68

22
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47

48
-continued

aaaaguaauu gugguuuuug cc

22

<210> SEQ ID NO 69
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 69

caaaaaccac aguuucuuuu gc

22

<210> SEQ ID NO 70
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 70

auauuaccau uagcucaucu uu

22

<210> SEQ ID NO 71
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 71

gaugagcuca uuguaauaug ag

22

<210> SEQ ID NO 72
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 72

aagaugugga aaaauuggaa

UC

22

<210> SEQ ID NO 73
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 73

auucuaauuu cuccacgucu uu

22

<210> SEQ ID NO 74
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 74

uucauuuggu auaaaccgcg auu

23

<210> SEQ ID NO 75
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 75

uugagaauga ugaaucauua gg

<210> SEQ ID NO 76
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 76

22
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-continued

ucuuguguuc ucuagaucag u

21

<210> SEQ ID NO 77
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

77

gagcuuauuc auaaaagugc ag

22

<210> SEQ ID NO 78
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

78

uaauuuuaug uauaagcuag u

21

<210> SEQ ID NO 79
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

79

cacaagguau ugguauuacc u

21

<210> SEQ ID NO 80
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

80

gugagucucu aagaaaagag ga

22

<210> SEQ ID NO 81
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

81

uuuaggauaa gcuugacuuu ug

22

<210> SEQ ID NO 82
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

82

aauggcgcca cuaggguugu g

21

<210> SEQ ID NO 83
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

83

uacccauugc auaucggagu ug

<210> SEQ ID NO 84
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens

22
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51
-continued
<400> SEQUENCE, 84
aaucauacac gguugaccua uu

<210>
<211>
<212>
<213>

22

SEQ ID NO 85
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 85
guucaaaucc agaucuauaa c

<210>
<211>
<212>
<213>

21

SEQ ID NO 86
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 86
aucacauugc cagggauuuc c

<210>
<211>
<212>
<213>

21

SEQ ID NO 87
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 87
aucacauugc cagggauuac c

<210>
<211>
<212>
<213>

21

SEQ ID NO 88
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 88
uucacagugg cuaaguucug c

<210>
<211>
<212>
<213>

21

SEQ ID NO 89
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 89
aggcaagaug cuggcauagc u

<210>
<211>
<212>
<213>

21

SEQ ID NO 90
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 90
gugcauugua guugcauugc a

<210>
<211>
<212>
<213>

21

SEQ ID NO 91
LENGTH, 20
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 91
gugcauugcu guugcauugc

<210>
<211>
<212>
<213>

SEQ ID NO 92
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

20
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53
-continued
<400> SEQUENCE, 92
uucaacgggu auuuauugag ca

<210>
<211>
<212>
<213>

22

SEQ ID NO 93
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 93

acaggugagg uucuugggag cc

<210>
<211>
<212>
<213>

22

SEQ ID NO 94
LENGTH, 24
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 94
ucccugagac ccuuuaaccu guga

<210>
<211>
<212>
<213>

24

SEQ ID NO 95
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 95
ucccugagac ccuaacuugu ga

<210>
<211>
<212>
<213>

22

SEQ ID NO 96
LENGTH, 23
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 96
acuccauuug uuuugaugau gga

<210>
<211>
<212>
<213>

23

SEQ ID NO 97
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 97
uaacacuguc ugguaaagau gg

<210>
<211>
<212>
<213>

22

SEQ ID NO 98
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 98
ugagaugaag cacuguagcu c

<210>
<211>
<212>
<213>

21

SEQ ID NO 99
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 99
uagguuaucc guguugccuu cg

<210> SEQ ID NO 100
<211> LENGTH, 23
<212> TYPE, RNA

22
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56
-continued

<213> ORGANISM,
<400>

Homo sapiens

SEQUENCE, 100

aacauucauu gcugucggug ggu

23

<210> SEQ ID NO 101
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 101

ugccuacuga gcugauauca gu

22

<210> SEQ ID NO 102
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 102

aacuggcccu caaagucccg cu

22

<210> SEQ ID NO 103
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 103

acaguagucu gcacauuggu ua

22

<210> SEQ ID NO 104
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 104

cccaguguuc agacuaccug uuc

23

<210> SEQ ID NO 105
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 105

cccaguguuu agacuaucug uuc

23

<210> SEQ ID NO 106
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 106

uaauacugcc ugguaaugau ga

22

<210> SEQ ID NO 107
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 107

uaauacugcc ggguaaugau gga

<210> SEQ ID NO 108
<211> LENGTH, 22

23
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57

58
-continued

<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 108

gugaaauguu uaggaccacu ag

22

<210> SEQ ID NO 109
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 109

uugugcuuga ucuaaccaug u

21

<210> SEQ ID NO 110
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 110

ugucaguuug ucaaauaccc ca

22

<210> SEQ ID NO 111
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 111

cuccuauaug augccuuucu

UC

22

<210> SEQ ID NO 112
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 112

gaacggcuuc auacaggagu u

21

<210> SEQ ID NO 113
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 113

aucacacaaa ggcaacuuuu gu

22

<210> SEQ ID NO 114
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 114

gaaguuguuc gugguggauu cg

22

<210> SEQ ID NO 115
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 115

acuucaccug guccacuagc cgu

<210> SEQ ID NO 116

23
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59
-continued
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 116

agcucggucu gaggccccuc agu

23

<210> SEQ ID NO 117
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 117

ugaggggcag agagcgagac uuu

23

<210> SEQ ID NO 118
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 118

uagugcaaua uugcuuauag ggu

23

<210> SEQ ID NO 119
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 119

aaaccguuac cauuacugag uu

22

<210> SEQ ID NO 120
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 120

ucaggcucag uccccucccg au

22

<210> SEQ ID NO 121
<211> LENGTH, 20
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 121

auuccuagaa auuguucaua

20

<210> SEQ ID NO 122
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 122

uaauacuguc ugguaaaacc gu

22

<210> SEQ ID NO 123
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 123

ugucuugcag gccgucaugc a

21
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62
-continued

<210> SEQ ID NO 124
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

124

aacuguuugc agaggaaacu ga

22

<210> SEQ ID NO 125
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

125

cucaucugca aagaaguaag ug

22

<210> SEQ ID NO 126
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

126

ugaaacauac acgggaaacc

UC

22

<210> SEQ ID NO 127
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

127

cagcagcaca cugugguuug u

21

<210> SEQ ID NO 128
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

128

ccucuagaug gaagcacugu cu

22

<210> SEQ ID NO 129
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

129

cuaauaguau cuaccacaau aaa

23

<210> SEQ ID NO 130
<211> LENGTH, 24
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

130

acugggggcu uucgggcucu gcgu

24

<210> SEQ ID NO 131
<211> LENGTH, 24
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

131

aaagacauag gauagaguca ccuc

24
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-continued
<210> SEQ ID NO 132
<211> LENGTH, 19
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 132

aagugugcag ggcacuggu

19

<210> SEQ ID NO 133
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 133

uucccuuugu cauccuucgc cu

22

<210> SEQ ID NO 134
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 134

agaucgaccg uguuauauuc gc

22

<210> SEQ ID NO 135
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 135

aucauagagg aaaauccacg u

21

<210> SEQ ID NO 136
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 136

aucauagagg aaaauccaug uu

22

<210> SEQ ID NO 137
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 137

ugguagacua uggaacguag g

21

<210> SEQ ID NO 138
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 138

gugacaucac auauacggca gc

22

<210> SEQ ID NO 139
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 139

uuuugcaccu uuuggaguga a

21
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66
-continued

<210> SEQ ID NO 140
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 140

uacccuguag aaccgaauuu gug

23

<210> SEQ ID NO 141
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 141

aacccguaga uccgaucuug ug

22

<210> SEQ ID NO 142
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 142

aacccguaga uccgaacuug ug

22

<210> SEQ ID NO 143
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 143

uauggcuuuu uauuccuaug uga

23

<210> SEQ ID NO 144
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 144

uauggcuuuu cauuccuaug uga

23

<210> SEQ ID NO 145
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 145

ucuggcuccg ugucuucacu

CCC

23

<210> SEQ ID NO 146
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 146

uucccuuugu cauccuaugc cu

<210> SEQ ID NO 147
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 147

22

US 8,936,909 B2

67

68
-continued

uggcagugua uuguuagcug gu

22

<210> SEQ ID NO 148
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

148

aggcagugua uuguuagcug gc

22

<210> SEQ ID NO 149
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

149

ugauuguagc cuuuuggagu aga

23

<210> SEQ ID NO 150
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

150

uacuccagag ggcgucacuc aug

23

<210> SEQ ID NO 151
<211> LENGTH, 18
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

151

uucacaggga ggugucau

18

<210> SEQ ID NO 152
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

152

aucgugcauc ccuuuagagu gu

22

<210> SEQ ID NO 153
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

153

cucuagaggg aagcacuuuc

UC

22

<210> SEQ ID NO 154
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

154

caaagugccu cccuuuagag ug

<210> SEQ ID NO 155
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

155

22
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-continued

aagugccucc uuuuagagug uu

<210>
<211>
<212>
<213>

22

SEQ ID NO 156
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 156
aaagugcuuc ccuuuggacu gu

<210>
<211>
<212>
<213>

22

SEQ ID NO 157
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 157
aaagugcuuc cuuuuugagg g

<210>
<211>
<212>
<213>

21

SEQ ID NO 158
LENGTH, 24
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 158
acaaagugcu ucccuuuaga gugu

<210>
<211>
<212>
<213>

24

SEQ ID NO 159
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 159
acaaagugcu ucccuuuaga gu

<210>
<211>
<212>
<213>

22

SEQ ID NO 160
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 160
uacugcagac guggcaauca ug

<210>
<211>
<212>
<213>

22

SEQ ID NO 161
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 161

ugauugguac gucugugggu ag

<210>
<211>
<212>
<213>

22

SEQ ID NO 162
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 162
auugacacuu cugugaguag a

<210>
<211>
<212>
<213>

SEQ ID NO 163
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

21
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72
-continued

<400>

SEQUENCE, 163

ugcuuccuuu cagagggu

18

<210> SEQ ID NO 164
<211> LENGTH, 20
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 164

cugcaaaggg aagcccuuuc

20

<210> SEQ ID NO 165
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 165

gaaagcgcuu cccuuugcug ga

22

<210> SEQ ID NO 166
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 166

caaagcgcuu cucuuuagag ugu

23

<210> SEQ ID NO 167
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 167

aaagcgcuuc ccuucagagu g

21

<210> SEQ ID NO 168
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 168

uucuccaaaa gggagcacuu

UC

22

<210> SEQ ID NO 169
<211> LENGTH, 20
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 169

cuacaaaggg aagcccuuuc

20

<210> SEQ ID NO 170
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 170

aaagugcuuc ucuuuggugg gu

<210> SEQ ID NO 171
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens

22
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-continued
<400> SEQUENCE, 171

gaaggcgcuu cccuuuggag u

<210>
<211>
<212>
<213>

21

SEQ ID NO 172
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 172
cuacaaaggg aagcacuuuc uc

<210>
<211>
<212>
<213>

22

SEQ ID NO 173
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 173
cucuagaggg aagcacuuuc ug

<210>
<211>
<212>
<213>

22

SEQ ID NO 174
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 174
ugacaacuau ggaugagcuc u

<210>
<211>
<212>
<213>

21

SEQ ID NO 175
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 175
cuucuugugc ucuaggauug u

<210>
<211>
<212>
<213>

21

SEQ ID NO 176
LENGTH, 23
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 176

gcgaggaccc cucggggucu gac

<210>
<211>
<212>
<213>

23

SEQ ID NO 177
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 177

uggcaguguc uuagcugguu gu

<210>
<211>
<212>
<213>

22

SEQ ID NO 178
LENGTH, 20
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 178

uaaggcacgc ggugaaugcc

<210> SEQ ID NO 179
<211> LENGTH, 23
<212> TYPE, RNA

20
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<213> ORGANISM,
<400>

Homo sapiens

SEQUENCE, 179

aaagugcugc gacauuugag cgu

23

<210> SEQ ID NO 180
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 180

aaugcaccug ggcaaggauu ca

22

<210> SEQ ID NO 181
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 181

auccuugcua ucugggugcu a

21

<210> SEQ ID NO 182
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 182

aacgcacuuc ccuuuagagu gu

22

<210> SEQ ID NO 183
<211> LENGTH, 20
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 183

auguauaaau guauacacac

20

<210> SEQ ID NO 184
<211> LENGTH, 19
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 184

gagccaguug gacaggagc

19

<210> SEQ ID NO 185
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 185

uacccuguag auccgaauuu gug

23

<210> SEQ ID NO 186
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 186

uuauugcuua agaauacgcg uag

<210> SEQ ID NO 187
<211> LENGTH, 22

23
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<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

187

uccuucauuc caccggaguc ug

22

<210> SEQ ID NO 188
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

188

uggaauguaa ggaagugugu gg

22

<210> SEQ ID NO 189
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

189

auaagacgag caaaaagcuu gu

22

<210> SEQ ID NO 190
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

190

auaagacgaa caaaagguuu gu

22

<210> SEQ ID NO 191
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

191

aaaucucugc aggcaaaugu ga

22

<210> SEQ ID NO 192
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

192

uaaucucagc uggcaacugu ga

22

<210> SEQ ID NO 193
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

193

uaagugcuuc cauguuuugg uga

23

<210> SEQ ID NO 194
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

194

acuuuaacau ggaagugcuu

<210> SEQ ID NO 195

UC

22
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<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

195

uaagugcuuc cauguuucag ugg

23

<210> SEQ ID NO 196
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

196

uuuaacaugg ggguaccugc ug

22

<210> SEQ ID NO 197
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

197

ugucugcccg caugccugcc ucu

23

<210> SEQ ID NO 198
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

198

agaucagaag gugauugugg cu

22

<210> SEQ ID NO 199
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

199

uuucaagcca gggggcguuu uuc

23

<210> SEQ ID NO 200
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

200

uuaagacuug cagugauguu u

21

<210> SEQ ID NO 201
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

201

aacaucacag caagucugug cu

22

<210> SEQ ID NO 202
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

202

ugauugguac gucugugggu ag

22
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<210> SEQ ID NO 203
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

203

uacucaggag aguggcaauc ac

22

<210> SEQ ID NO 204
<211> LENGTH, 24
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

204

uucuccaaaa gaaagcacuu ucug

24

<210> SEQ ID NO 205
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

205

ucucuggagg gaagcacuuu cug

23

<210> SEQ ID NO 206
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

206

aaagugcauc cuuuuagagg uu

22

<210> SEQ ID NO 207
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

207

cucuagaggg aagcgcuuuc ug

22

<210> SEQ ID NO 208
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

208

cuccagaggg augcacuuuc u

21

<210> SEQ ID NO 209
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

209

gaaggcgcuu cccuuuagag cg

22

<210> SEQ ID NO 210
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

210

cucuugaggg aagcacuuuc ugu

23
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<210> SEQ ID NO 211
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 211

caagaaccuc aguugcuuuu gu

22

<210> SEQ ID NO 212
<211> LENGTH, 22
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 212

aaaaguaauu gugguuuugg cc

22

<210> SEQ ID NO 213
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 213

gcgacccacu cuugguuucc a

21

<210> SEQ ID NO 214
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 214

aaaacgguga gauuuuguuu u

21

<210> SEQ ID NO 215
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 215

uagauaaaau auugguaccu g

21

<210> SEQ ID NO 216
<211> LENGTH, 23
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 216

acuuacagac aagagccuug

CUC

23

<210> SEQ ID NO 217
<211> LENGTH, 19
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 217

aggcugcgga auucaggac

19

<210> SEQ ID NO 218
<211> LENGTH, 21
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400>

SEQUENCE, 218

aaacuacuga aaaucaaaga u

21
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<210>
<211>
<212>
<213>

SEQ ID NO 219
LENGTH, 22
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 219
acuuguaugc uagcucaggu ag

<210>
<211>
<212>
<213>

22

SEQ ID NO 220
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 220
guggcugcac ucacuuccuu c

<210>
<211>
<212>
<213>

21

SEQ ID NO 221
LENGTH, 25
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 221

ggcggaggga aguagguccg uuggu

<210>
<211>
<212>
<213>

25

SEQ ID NO 222
LENGTH, 23
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 222
caguaacaaa gauucauccu ugu

<210>
<211>
<212>
<213>

23

SEQ ID NO 223
LENGTH, 23
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 223
uucucgagga aagaagcacu uuc

<210>
<211>
<212>
<213>

23

SEQ ID NO 224
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 224
aggguaagcu gaaccucuga u

<210>
<211>
<212>
<213>

21

SEQ ID NO 225
LENGTH, 19
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 225
ugagcugcug uaccaaaau

<210>
<211>
<212>
<213>

SEQ ID NO 226
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 226

19
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21

aguuaaugaa uccuggaaag u

<210>
<211>
<212>
<213>

SEQ ID NO 227
LENGTH, 21
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

227
21

uuuccauagg ugaugaguca c

The invention claimed is:
1. A method for determining the type of a forensic sample,
comprising:
a. obtaining RNA from the forensic sample; and
b. analyzing expression of at least two marker miRNAs or
isoforms thereof, in the forensic sample,
'
wherein based on the expression of the miRNAs, or isoforms thereof, the type of forensic sample is determined
to be blood, menstrual blood, semen, vaginal secretion
or saliva
and wherein determining the sample is blood comprises
analyzing expression of at least two miRNAs listed in
Table 1, determining the sample is menstrual blood comprises analyzing expression of at least two miRNAs
listed in Table 2, determining the sample is semen comprises analyzing expression of at least two miRNAs
listed in Table 3, determining the sample is vaginal
secretion comprises analyzing expression of at least two
miRNAs listed in Table 4, and determining the sample is
saliva comprises analyzing expression of at least two
miRNAs listed in Table 5.
2. The method according to claim 1, comprising analyzing
at least three marker miRNAs.
3. The method according to claim 1, wherein
a. the miRNAs, or isoforms thereof, are expressed in the
forensic sample and serve as a marker;
b. the miRNAs, or isoforms thereof, show a discriminating/
differential expression pattern in a particular type of
forensic sample compared to other types of forensic
samples;
c. the miRNAs, or isoforms thereof, are specifically
expressed in a particular type of forensic sample; and/or
d. the miRNAs, or isoforms thereof, are expressed in higher
abundance in a particular type of forensic sample.
4. The method according to claim 1, wherein at least two
marker miRNAs, or isoforms thereof, are detected as markers
for one particular forensic sample type, and/or wherein at
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least ~o marker miRNAs, or isoforms thereof, specific for
each d1ff~rent.forensic sample type are analyzed in parallel in
order to identify the type of forensic sample.
5. The method according to claim 1, wherein
a. the at least two miRNAs, or isoforms thereof, for determining blood are selected from the group consisting of
miR15a, Let7i, miR15b, miR16, miR106a, miR106b,
miR126, miR182, miR182*, miR185 miR190
miR195, miR374, miR451, miR545 miR624 miR627'
miR154*, andmiR607;
'
'
'
b. the at least two miRNAs, or isoforms thereof, for determining menstrual blood are selected from the group
consisting of miR33, miR23a/b miR95 miR106b
miR154, miR218, miR377, miR4i'2, miR423, miR425~
3p, miR451, miR452, miR452* miR484 miR494
miR648, miR369-5p, miR507, and miR648;'
'
c. the at least two miRNAs, or isoforms thereof, for determining semen are selected from the group consisting of
miRlOb, miR99a, miR135a, miR135b, miR204,
miR508, miR513, miR517a, miR518f*, miR519d,
miR520a*, miR520g/h, miR514, miR518c miR518e
miR524*, andmiR611;
'
'
d. the at least two miRNAs, or isoforms thereof, for determining vaginal secretion are selected from the group
consisting ofmiR195, miR124a, miR372, miR521, and
miR568; and/or
e. the at least two miRNAs, or isoforms thereof for determining saliva are selected from the group co~sisting of
miR205, miR206, miR208, miR302c, miR509,
miR510, miR515-5p, miR518c*, miR525, miR526b,
miR551a, miR600, miR606, miR555, miR587, and
miR658.
6. The method of claim 1, further comprising reverse transcribing the obtained RNA prior to the analyzing.
7. The method of claim 6, further comprising quantifying
the obtained RNA.
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